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ABSTRACT            
Amanda Beth Keener: Requirements for memory B cell and long lived plasma cell development 
during adaptive immune responses and Staphylococcus aureus infection                               
(Under the direction of Barbara Vilen)                                            
Memory B cells and plasma cells (PCs) are terminally differentiated B cells that 
contribute to recall responses vital for protection against infections. Formation of high affinity 
memory B cells requires cognate T cell help, somatic hypermutation and affinity maturation 
within germinal centers (GCs); however, the signals that commit B cells to the GC and the 
memory pool remain unclear. This work identifies IgG immune complexes (ICs), FcγRs, and 
BAFF as vital players in the GC response and formation of memory B cells. Early secretion of 
IgG lead to IC-FcγR interactions that induced dendritic cells to secrete BAFF, which in turn 
promoted Bcl-6 expression in activated B cells. Loss of FcγRIII, hematopoietic cell-derived 
BAFF, or blocking Ig-Fc regions all diminished the expression of Bcl-6, the frequency of GC 
and memory B cells, and secondary antibody responses.  This work highlights a key role for IC-
FcγR interactions in B cell fate decisions. 
 ICs may be targeted by pathogens known to disrupt adaptive immune responses, like 
Staphylococcus aureus.  Infection with S. aureus does not induce long-lived protective 
immunity.  Although vaccine studies in mice and humans support the role of antibodies in 
protecting against recurring infections, it is not clear whether memory B cells or long-lived 
plasma cells are formed after S. aureus infection. The activity of B cells in response to S. aureus 
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is compromised by Protein A (SpA), a surface protein that interferes with IgG-FcγR interactions 
and opsonization of the bacteria, and induces polyclonal expansion of VhIII B cells. Using a SpA 
deletion mutant, we found that GCs, antibody responses, and memory B cell formation were 
unaffected by the presence of SpA. However, SpA drove an enhanced short-lived extrafollicular 
response and reduced the pool of long-lived bone marrow resident PCs that were derived from 
activated memory B cells. This led to a rapid decline in antigen-specific, class-switched 
antibody. Thus, failure to establish long-term protective antibody titers against S. aureus was not 
a consequence of diminished B cell memory formation, but a lack of long-term antibody 
maintenance.   
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CHAPTER1: INTRODUCTION 
 
Adaptive immune responses 
 
Successful activation of the adaptive immune response results in long-term 
immunological memory, which protects against re-infection. Memory B and T cells are long-
lived, antigen-specific cells with the capacity to mount rapid and expanded responses upon 
secondary exposure to antigens or pathogens [1]. Memory responses form the basis of 
vaccination and protection from re-exposure to commonly encountered pathogens. Despite this, 
the adaptive immune mechanisms required for memory, particularly for memory to bacterial 
pathogens, are not completely understood. This understanding is needed in order to design 
vaccines that are best suited for their target pathogens and target populations.  
Antibody production by B cells is a major arm of immune memory. The selection and 
survival of memory B cells during a primary adaptive immune response is a carefully regulated 
process. Initial activation of naïve B cells via B cell receptors (BCRs) causes them to migrate to 
T cell-rich areas of secondary lymphoid organs in search of cognate interaction and co-
stimulation [2,3]. T cell help allows B cells to respond to antigen and proliferate. Proliferating 
cells differentiate into short-lived antibody-secreting cells (ASCs) or are recruited into structures 
called germinal centers (GCs) within the B cell follicle [4,5].  Both pathways can result in BCR 
isotype switching from immunoglobulin (Ig) M or D to IgG since activation-induce deaminase 
(AID) is activated during the initial T:B interaction [2].   
2 
 
Both ASC and GC pathways may also be T cell-dependent or independent [6,7]. High 
affinity or avidity BCR ligation and/or Toll-like receptor (TLR) signaling may initiate T-
independent B cell responses [6,8]. In general, T-independent responses drive short-term 
proliferation of ASCs in extrafollicular foci, (though extrafollicular responses may also involve 
T cell help), and T-dependent responses promote GC recruitment. 
The Germinal Center 
 
Early in the immune response, follicular dendritic cells (FDCs) create a reticular network 
that presents Ag to B and T cells and secretes chemokines such as CXCL13 to bring cells 
together to form GC structures [5,9]. Within GCs, T follicular helper cells (Tfh) provide co-
stimulation and survival signals to GC B cells, through interactions like CD40:CD40L and 
ICOS:ICOSL [10]. More recently, Tfh cells have been shown to produce local levels of BAFF 
within GCs to support affinity maturation of GC B cells in closest contact with Tfh cells [11].  
Tfh cells and FDCs provide survival signals for GC B cells as they undergo clonal 
expansion, somatic hypermutation, and affinity maturation. Over time, B cell clones with BCRs 
of high affinity and specificity for antigen are selected for survival, while other clones die via 
apoptosis [9,12]. During this process, expression of the transcription factor, Bcl-6 directs B cells 
to maintain a GC phenotype and withstand the DNA mutations required for somatic 
hypermutation [9,13]. Signals from Tfh cells, in particular IL-21, contribute to the maintenance 
of Bcl-6 expression by GC B cell [13,14]. Although Bcl-6 is required for GC B cells, the factors 
required to initiate Bcl-6 expression in B cells are not well defined.  
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Memory B cells 
 
The ultimate products of the GC reaction are memory B cells and affinity matured plasma 
cells (PCs). The mechanisms that drive one fate over the other are on an ongoing area of 
investigation. Expression of the transcriptional master regulator, Blimp-1, along with XBP-1 and 
IRF-4, direct plasmablast (PB) and PC differentiation [15–17]. The transcriptional control of 
memory B cell development is less clear. Blimp-1 and Bcl-6 are mutually repressive [13,18,19], 
but complete differentiation of memory B cells requires that Bcl-6 ultimately be downregulated 
[18]. Further, Bcl-6 and GCs are dispensable for generating low-affinity, under-mutated memory 
B cells [18,20], although secondary responses are impaired when the primary GC reaction is 
disrupted [1,10].  
Memory B cells are long-lived, quiescent, antigen-specific cells, capable of mounting a 
rapid and robust antibody response upon re-exposure to antigen [21,22]. Classically, memory B 
cells have been defined as having high affinity class-switched BCRs; however, in recent years, it 
has become clear that memory B cells can be formed without class switching or even T cell help 
[23,24]. Both IgM
+ 
and IgG
+ 
memory B cells participate in rapid secondary responses; IgM
+ 
memory cells contribute to secondary GCs and IgG
+ 
memory cells produce PBs/ASCs that make 
high affinity IgG [25–27].  
Memory B cells are uniquely poised to respond quickly to their cognate antigen. Memory 
B cells typically localize close to T cells and constitutively express co-stimulatory molecules, 
which allows them quickly obtain T cell help in a secondary response [22,26,28]. Both 
circulating IgG from the primary response and high BCR affinity improve antigen presentation 
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and T cell help [28]. Finally, genetic and epigenetic changes to anti-apoptotic and pro-cell cycle 
genes allow memory B cells to survive for long periods of time and divide rapidly when they re-
engage antigen [22,29]. 
Plasma cells 
 
Plasma cells are terminally-differentiated B cells that secrete antibody but do not divide. 
There are many paths leading to PC differentiation. First, primary T-dependent or T-independent 
responses can lead to short-term proliferation of antibody-secreting, dividing PBs in the 
extrafollicular spaces of secondary lymphoid organs [6,30]. These cells produce an early surge of 
low affinity antibody and may undergo somatic hypermutation outside the GC [31]. As PBs 
mature, they lose surface expression of B cell markers like B220, CD19 and the BCR and cease 
dividing and become PCs [2,30]. Second, PCs may come out of the GC reaction. Post-GC PCs 
typically secrete more highly mutated, higher affinity antibody [32]. Third, during a secondary 
immune response, activated memory B cell clones divide and differentiate into PBs, many of 
which mature into PCs [32–37].  
Long-lived Plasma Cells 
 
Most PBs and PCs die within two weeks of forming [8,38,39], but some, particularly 
those derived from GCs or memory B cells, migrate to survival niches in the spleen, bone 
marrow (BM), or at sites of inflammation, and become long-lived plasma cells (LLPCs) [32]. 
LLPCs constitutively secrete antibody for years and perhaps for the lifetime of an organism 
[36,40]. It is not yet clear whether subsequent infections produce PCs that oust previously 
established LLPCs from long-term niches. There is evidence that this may be the case during 
severe infections [34,41], but not after immunization with common vaccines like polio, tetanus, 
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or diphtheria [42].  Activation of memory B cells results in the largest proportion of LLPCs, but 
they can be formed after primary immune responses [12,43]. It has been speculated that 
intermittent activation of memory B cells is required to repopulate the LLPC niche over time, but 
most evidence indicates that LLPCs persist in the absence of antigen [43] and are regulated 
independently of memory B cells [40,44,45]. 
There are no defining markers of LLPCs or of ASCs that are destined to become LLPCs. 
Blimp-1 is highest in BM LLPCs, and Blimp-1 expression increases in splenic ASCs as they 
mature, but it’s not clear if high Blimp-1 expression in the spleen is a pre-requisite for longevity 
in the BM [15]. Short and long-lived PCs express the glycoprotein CD138, which binds 
extracellular matrix, acts as a ligand for the PC survival factor, APRIL (A Proliferation-Inducing 
Ligand), and is expressed at higher levels as PCs mature [30,46,47]. T cell help and affinity 
maturation within the GC have both been implicated as prerequisites for LLPC differentiation 
[32,48]; however, it is possible for LLPCs to form without class switching or going through a 
GC reaction [49].  
PBs and PCs express chemokine receptors that direct them to extrafollicular spaces, 
toward medullary cords of secondary lymphoid organs, and out of those organs into the blood 
[2]. These include CXCR4, which follows CXCL12 toward extrafollicular spaces and later in the 
response, toward the bone marrow [33,50,51]. S1P1 is also required to exit secondary lymphoid 
organs into the blood [52,53].  
Though it is not clear whether the fate of LLPCs is designated before or after entry into 
the BM niche, it is clear that both PCs and PBs reach the niche and  must compete for limited 
survival factors. BM niche requirements are not completely defined, but they include stromal 
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cells, monocytes, eosinophils, and megakaryocytes [50,54]. Niche cells secrete APRIL, BCMA, 
CXCL12 and TNF-alpha [50,54–56]. These survival signals activate anti-apoptotic factors like 
Mcl-1 [57] and proteins like XBP-1 and ATG5 to regulate endoplasmic reticulum stress caused 
by constitutive Ig production[58–60]. Recently, the protein ZBTB20 has been described as a 
vital BM PC survival factor that is regulated as a result of adjuvant present during the immune 
response [61]. This supports the possibility that PC longevity is determined in secondary 
lymphoid organs before migration to the BM.  
Long-term immunity and Staphylococcus aureus infection 
 
LLPCs play an important role in immunity to viral, parasitic, and bacterial infections 
[35,44,49]. LLPCs constitutively secrete protective antibody that acts as an early line of defense 
and enhances secondary responses [35,49,62]. Therefore, it is vital to understand the mechanisms 
required for LLPC persistence. In the case of Staphylocuccus aureus infection, long-term 
maintenance of antigen-specific antibody is protective in humans [63–66]. However, S. aureus 
infections commonly recur and humoral immunity wanes unpredictably [67–71].  
S. aureus is one of the most common causes of skin and soft-tissue infections and up to 
65% of S. aureus infections are methicillin-resistant (MRSA), which is difficult to treat and life-
threatening when it causes a systemic infection [72–74]. Therefore, there is great interest in 
generating a vaccine to protect vulnerable populations against S. aureus infection. However, it 
remains unknown whether memory B cells or LLPCs are formed in response to S. aureus 
infection. 
S. aureus expresses many virulence factors that allow it to avoid or manipulate the 
immune response to infection and allow the bacteria to form abscesses in the skin or organs 
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[75,76]. The surface-expressed Staphylococcus protein A (SpA) is well known for its ability to 
impede B cell responses. SpA interferes with IgG-Fc receptor (FcγR) interactions by binding the 
Fc regions of IgG, interfering with opsonization and phagocytosis of S. aureus [77–79]. Work 
from our lab (Chapter 2) demonstrates that immune complex (IC) ligation of FcγRs induces B 
cell activating factor (BAFF) production by dendritic cells (DCs), which in turn directs B and T 
lymphocyte populations to generate GCs and memory.  Therefore we hypothesized that SpA 
blocks BAFF production by interfering with IC- FcγR interactions thereby reducing DC BAFF 
production and memory B cell formation. We used an isogenic Δspa mutant to examine DC 
BAFF (Appendix 1), B cell memory, and GC formation (Chapter 3) in the presence of absence of  
SpA during S. aureus exposure or infection. We found that SpA did not interfere with any of 
these outputs, and characterization of the primary B cell response to S. aureus revealed that 
memory B cells and secondary amnestic antibody responses were not affected by SpA. 
In addition to its interference with IgG- FcγR interactions, SpA can act as a super-antigen 
that binds naïve B cell receptors of the VhIII clan (up to 50% of naïve B cells in humans and 5-
10% in mice) [80,81], and drives polyclonal B cell proliferation [75,82]. Injection of purified 
SpA can also induce to B cell deletion due to the absence of a second signal, like TLR 
stimulation or T cell help [83].  Immunization with a SpA variant that cannot bind IgG Fc or IgM 
induces production of neutralizing anti-SpA antibodies and mice that produce such antibodies 
also produce higher titers of more diverse anti-S. aureus antibody specificities upon challenge 
infection.  These qualities have led to the hypothesis that SpA prevents B cell participation in the 
immune response to S. aureus [84].  We reasoned that SpA present during challenge infection 
may impede or alter memory B cell responses through its IgG-binding and/or super-antigen 
activity. We found that PB numbers were significantly increased by WT S. aureus compared to 
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challenge with Δspa. LLPCs, however, were only detectable after challenging mice with an 
Δspa, suggesting that SpA impedes either the migration or maturation of PC, or the retention and 
maturation of PC once they reach the BM. The physiological consequence of the lack of LLPC 
in WT-challenged mice was the waning of antigen-specific IgG production.  In Chapter 3, the 
nature of the secondary PB and PC response is examined in detail in an effort to determine how 
SpA impedes LLPC accumulation and antibody maintenance. 
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CHAPTER 2: IgG immune complexes promote B cell memory by inducing BAFF
1 
  
Introduction 
    
Adaptive immunity requires the commitment of activated B cells to either the memory or 
PC compartments, the differentiation of CD4
+
 T cells to Tfh cells, and coordinated expression of 
chemoattractant receptors to position T and B cells within the follicle for cognate interactions 
[3,85,86]. The specialized microenvironment of the GC provides a site for rapid expansion and 
selection of B cell clones whose somatically mutating Ig V regions compete for a limiting 
amount of antigen displayed on follicular dendritic cells [9,87–90].  Although many steps in the 
cyclic process of somatic hypermutation and clonal selection are defined, the events required to 
induce memory cell responses are incompletely understood [91–94].  
During the GC response, Tfh cells are critical effectors that provide help to B cells [3,95].  
Tfh cells engage activated B cells at the T:B border, and their secreted cytokines promote Ig 
isotype switching and the selection of cells with high affinity B cell receptors in GCs 
[13,85,96,97].  The expression of CXCR5, ICOS, PD-1, and the secretion of IL-21 distinguish 
Tfh cells from other CD4
+
 T cell subsets [98,99].  The formation of Tfh cells is dependent on the 
                                                          
1
 Amanda B. Keener*, Shannon Z. Jones*, SunAh Kang*, Robert J. Benschop, Alfredo Caro-
Maldonado, Jeffrey C. Rathmell, Stephen H. Clarke, Glenn K. Matsushima, Jason K. Whitmire, 
Barbara J. Vilen
 
(2014) IgG-immune complexes promote B cell memory by inducing DC-
derived BAFF (Unpublished work).*These authors contributed equally. 
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expression of Bcl-6, a process linked to ICOS expression on CD4
+ 
T cells [99,100] and 
influenced by IL-2 [101,102].  This commits primed T cells to the Tfh pool and inhibits their 
differentiation to other T cell subsets [103–105]. Bcl-6 is also required for GC B cell formation 
[103,106,107]. In activated B cells, Bcl-6 downregulates Blimp-1; thus, directing B cells away 
from PC differentiation and toward the memory pathway [17,108]. Cytokines such as IL-6 and 
IL-21 have been shown to affect Bcl-6 expression in B and T cells [14,109]; however detailed 
events upstream of Bcl-6 expression are of interest in understanding B and T cell differentiation 
in GC responses.   
BAFF plays an essential role in controlling the development and survival of B2 and 
marginal zone B cells [110,111], enhancing PB survival [112], and the survival of affinity-
matured B cells in the GC [11].  Early studies that neutralized BAFF suggested BAFF played a 
role in the GC response; however, interpretations of those results were complicated by the loss of 
B cells associated with BAFF depletion [113–116].  Others have shown that BAFF and anti-
CD40 increase ICOSL expression on B cells [117], and that TACI serves to limit the expression 
of ICOSL and the expansion of Tfh cells and GC B cells [118].  These studies suggest an indirect 
role for BAFF family members and CD40L in the formation of Tfh cells through ICOS:ICOSL 
interactions.  Thus, BAFF has been implicated in events that contribute to GC responses; 
however, how BAFF is induced and where it acts in the GC response remains unclear. 
In this study we identify a previously unrecognized role for IgG-ICs, CD16, and BAFF in 
the formation of B cell memory.  We found that early production of anti-NP-IgG promotes the 
formation of ICs that activate DCs through CD16.  This induces the secretion of BAFF, which 
acts upstream of Bcl-6 to promote the formation of GC B cells and proper memory cell 
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formation. Although BAFF is not involved in the formation of Tfh cells, it plays a role in 
stabilizing the population at the peak of the GC response.  Thus, IgG-ICs and FcγRs, through 
BAFF, act at or upstream of Bcl-6 expression in GC B cells and in the maintenance of Tfh cells 
to support the formation of B cell memory.   
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Results 
 
BAFF
-/-
 bone marrow chimeras exhibit reduced secondary responses 
Previous studies have linked BAFF with an enhanced response to vaccination, suggesting 
that it plays a role in adaptive immune responses [119–121].  To assess this, we generated BAFF-
/-
 bone marrow chimeras by engrafting irradiated B6 mice with B6 (BAFF
+/+
) or BAFF
-/-
 bone 
marrow.  This approach limits BAFF deficiency to hematopoietic cells, allowing other sources of 
BAFF to maintain the peripheral B cell population [122] (data not shown).  In BAFF
-/-
 chimeras, 
we found that the primary IgG response to NP14KLH (Figure 1A) was comparable to B6 control 
chimeras.  However, 14 days after secondary immunization, the BAFF
-/-
 bone marrow chimeras 
showed a 2-fold reduction in the levels of IgG compared to B6 chimeric control mice (1.4-fold 
lower on day 42) (Figure 1B).  The reduced IgG during the secondary response could reflect 
diminished class switch since BAFF can induce AID expression [123,124].  However, AID 
mRNA levels in B cells from B6 control and BAFF
-/-
 chimeras were not different (data not 
shown), suggesting that BAFF has a role other than in class switch.    
 
BAFF
-/-
 chimeras exhibit defects in the frequency of memory B, Tfh cells, and GC B cells 
Rapid, high titer secondary immune responses require the activation of memory B cells 
[1]. Although IgG memory B cells do not require BAFF for maintenance [125], it is not known 
whether BAFF is important for their formation.  To determine whether BAFF affects the 
frequency of memory B cells, we immunized BAFF
-/-
 chimeras with NP14KLH and measured the 
frequency of NP-specific memory B cells (CD19
+
IgG
+
Ac38 Id
+
) on day 28 post-immunization.  
We found that in B6 mice, immunization significantly increased the frequency of memory B 
cells, but not in the BAFF
-/-
 bone marrow chimeras (Figure 1C).   
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Tfh cells are critical to the early GC response and required for the differentiation of 
memory B cells [126–128].  It is possible that BAFF affected memory responses by influencing 
germinal center responses and/or Tfh cells.  To assess whether BAFF affects formation and 
maintenance of Tfh cells, B6 and BAFF
-/-
 chimeras were immunized and the frequencies of Tfh 
cells (CXCR5
+
PD-1
+
CD4
+
) were quantitated on days 3 and 7 post-immunization (Figure 1D 
and 1E).  On day 3, the frequency of Tfh cells in B6 chimeras increased by 1.5-fold while in 
BAFF
-/-
 chimeras it increased 1.2-fold.  This suggests that BAFF does not play a significant role 
in the formation of Tfh cells.  However on day 7 post-immunization, B6 chimeras displayed an 
increased frequency (1.9-fold) of Tfh cells, whereas their frequency in BAFF
-/-
 chimeras did not 
change.  This suggests that BAFF may stabilize Tfh cells or support their expansion.  
Germinal centers are necessary for the formation of high affinity, class-switched memory 
B cells [129,130].  To determine whether BAFF impacted the frequency of GC B cells, we 
enumerated CD19
+
GL-7
+
CD95
+
 GC B cells 7 days after immunization.  In BAFF
-/-
 chimeras, the 
frequency of total (Figure 1F and 1G) and Ag-specific (Figure 1H; CD19
+
Ac38
+
IgG
+
GL-
7
+
CD95
+
) GC B cells in BAFF
-/- 
chimeras was lower than the response in B6 chimeras.  Thus, 
BAFF significantly contributes to antigen-specific GC responses. 
 
BAFF acts at or upstream of Bcl-6 expression in B cells  
Bcl-6 plays a critical role in initiating GC responses and committing activated B cells to a 
memory cell phenotype [106,131,132].  Thus, one possibility is that BAFF affected Bcl-6 
expression.  To test this, we measured Bcl-6 levels in GC B cells after immunization.  We found 
that on day 7, the levels of Bcl-6 in GC B cells from immunized BAFF
-/-
 chimeras were lower 
than in B6 chimeras (Figure 1I and 1J).  The data show that hematopoietic cell-derived BAFF 
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acts at, or upstream of, Bcl-6 expression in B cells.  Collectively, our data indicate that BAFF 
impacts the expansion and stabilization of the Tfh cell pool, and the formation of GC and 
memory B cells.    
 
DC-derived BAFF regulates the frequency of GC B and Tfh cells  
Myeloid cells are a major source of BAFF following infection or immunization 
[112,119,133].  To assess whether the source of BAFF that impacted the GC response was 
derived from DCs or macrophages (MFs), we adoptively transferred bone marrow-derived 
dendritic cells (BMDCs) and bone marrow-derived macrophages (BMMFs) from BAFF 
transgenic (Tg) mice into BAFF
-/-
 chimeras
 
by subcutaneous injection (s.c.) at the time of 
immunization.  We reasoned that if BAFF was required for the maintenance of Tfh cells or the 
formation and/or maintenance of GC B cells, then enforced expression of BAFF by DCs and/or 
MFs might restore their frequencies.  We previously established that 70% of s.c. injected 
BMDCs migrated to the inguinal lymph nodes, and that the magnitude of the subcutaneous anti-
NP response was comparable to intraperitoneal (i.p.) immunization (data not shown).  We found 
that constitutive expression of BAFF by Tg DCs, but not Tg MFs, restored the frequencies of GC 
B cells (Figure 2A), Tfh cells (Figure 2B), and the levels of Bcl-6 in GC B cells (Figure 2C).  
Conversely, transfer of BAFF
-/-
 DCs did not increase the frequencies of GC B cells (Figure 2A), 
indicating that the effects were not due to an increased number of DCs, or the secretion of other 
cytokines through activation of the transferred DCs. Thus, the previously reported role for DCs 
in the induction of GC and Tfh cells [134] might also involve BAFF.   
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The binding of immune complex to FcγRs induces BAFF secretion  
Previous studies showed that exogenous ICs induce BMDCs to secrete a number of 
cytokines, including BAFF [135,136].  In another study, mice lacking the common gamma chain 
of the FcγRs (Fcγc) exhibited diminished secondary immune responses [62].  Because our data 
suggest that DCs may promote secondary responses via BAFF, we postulated that ICs formed by 
the early IgG antibody response might induce DCs to secrete BAFF.  This model requires that 
the early IgG response occur concurrently, or precede BAFF secretion. To test this, we harvested 
spleens from B6 mice on days 2, 3, and 7 following NP14KLH immunization and used ELISpot 
to measure the numbers of antibody (IgG) secreting cells (ASCs) and BAFF-secreting DCs.  NP-
specific (IgG) ASCs were present in the spleen by day 2 post-immunization and expanded over 
the course of 7 days (Figure 2D).  Similarly, the number of splenic CD11c
+
 DCs that secreted 
BAFF increased 6-fold between days 2 and 7 (Figure 2E).  Thus, secretion of Ig by B cells, and 
production of BAFF by DCs, occurs simultaneously beginning approximately 2 days following 
immunization.  This is consistent with the idea that IgG-ICs induce BAFF, which contributes to 
GC responses.   
To further test the idea that IgG-ICs induce DCs to secrete BAFF, we blocked IgG-
Fc:FcγRs interactions in vitro and assessed whether this impacted BAFF secretion by DCs.  
Stimulation of B6 BMDCs with pre-formed IgG-ICs (IgM bound by anti-μ) induced a1.8-fold 
increase in BAFF secretion (Figure 2F).  This was not unique to IgM/IgG ICs because 
preformed anti-NP ICs (NP-OVA bound by anti-NP) stimulated a dose dependent 2.5-fold 
increase in BAFF secretion (data not shown).   However, co-culture with a tetrameric tripeptide 
(TG19320) that blocks IgG Fc regions [137–139] reduced the number of BAFF-secreting DCs to 
levels indistinguishable from unstimulated cells.  
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To assess whether blocking Fc:FcγR interactions affected the adaptive immune response 
in vivo, we administered TG19320 at the time of immunization and measured the frequencies of 
GC B and Tfh cells.  We found that co-administration of TG19320 with NP14KLH blocked an 
increase in GC B and Tfh cells on day 7 (Figure 2G and 2H).  This indicates that the 
interactions between IgG-ICs and FcγRs are necessary for optimal GC responses and for the 
stabilization of Tfh cells in response to immunization.  Collectively, these data identify a 
mechanism wherein IgG-ICs formed early in the immune response ligate FcγRs on DCs to 
induce BAFF secretion, which in turn contributes to the GC response.   
 
BAFF regulates the expression of Bcl-6 in activated B cells in vitro 
To define whether the effects of BAFF on activated B cells was direct, we established an 
in vitro reconstitution system using the expression of Bcl-6 as a marker of memory B cell 
commitment. In this model, B6 B cells were stimulated with anti-μ in combination with IL-4 and 
IL-5 to induce Ig secretion and a low level of Bcl-6 expression (Figure 3A and B).  These 
activated B cells were then cultured in conditioned medium (CM) prepared from DCs treated 
with preformed IgG1-ICs (DC CM).  Addition of DC CM increased Bcl-6 expression to 
approximately 3-fold over unstimulated B cells (Figure 3A and 3B).  These levels were 
comparable to those achieved with recombinant BAFF.  Bcl-6 expression was dependent on Ig-
Fc regions as CM from DCs stimulated with F(ab’)2-containing ICs were ineffective at inducing 
Bcl-6 (Figure 3C).  In this in vitro system, Bcl-6 expression was not induced in B cells cultured 
with DC CM where BAFF was neutralized with BR3-Fc, or where DC CM was made from 
BAFF
-/-
 DCs (Figure 3C).  As Bcl-6 levels become elevated, the plasma cell program is 
attenuated [17,140]. To further validate the in vitro model, we measured intracellular IRF-6 and 
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XBP-1 and found that DC CM diminished the levels of both transcription factors by 2.2-fold 
(Figure 3D-G), indicating that BAFF may act at or upstream of Bcl-6, directing B cell 
differentiation away from a plasma cell fate.    
 
IgG-ICs bind CD16 during the anti-NP response   
We reasoned that if FcγR stimulation promoted BAFF secretion, loss of the FcγR(s) that 
binds IgG1-anti-NP ICs would negatively affect the ability of DC CM to promote Bcl-6. To 
assess this, we tested whether CMs from BMDCs derived from B6 mice, or mice deficient in 
CD64 (FcγRI-/-), CD32 (FcγRIIb -/-), CD16 (FcγRIII -/-), or CD16-2 (FcγRIV-/-) induced Bcl-6 in 
the in vitro reconstitution system described above. DC CM from CD16
-/- 
mice failed to induce 
Bcl-6 expression, while CMs from all other FcγR deficient mice induced Bcl-6 to levels 
comparable to, or above those induced by B6 DC CM (Figure 3H).  This suggests that ligation 
of CD16 on DCs is required for the expression of Bcl-6 in B cells.   
 
Impaired secondary responses in CD16
-/-
 mice 
Our data indicate that CD16 might be responsible for inducing DCs to secrete BAFF after 
NP14KLH immunization. To test this in vivo, we quantitated the number of splenic BAFF 
secreting DCs in B6 and CD16
-/-
 mice 7 days after immunization (Figure 4A).  In the absence of 
CD16, we found that the number of BAFF secreting DCs was markedly diminished compared to 
wild type mice.  This is consistent with the idea that CD16 is the FcγR responsible for initiating 
the IgG1-dominant immune response to NP-KLH [130].  
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To test whether loss of CD16 in vivo impaired adaptive immune responses, we measured 
primary and secondary antibody responses in B6 and CD16
-/-
 mice following NP14KLH 
immunization.  As in the BAFF
-/-
 chimeric mice, the primary IgG response in CD16
-/-
 mice was 
comparable to B6 mice (Figures 4B).  In the secondary response, the levels of IgG in B6 mice 
increased 1.7-fold on day 42 (7 days after boost), and 4.5-fold on day 49 (14 days after boost), 
while IgG levels in the CD16
-/-
 mice did not increase on days 42 or 49 (Figure 4C).  This was 
not an indirect consequence of altered cell populations due to CD16 deficiency since the 
frequencies of DCs, T, and B cells in CD16
-/-
 mice were not different than B6 mice (data not 
shown).   This indicates that CD16 plays a role in generating memory B cells and secondary 
immune responses to NP-KLH.   
 
CD16
-/-
 mice exhibit defects in forming Tfh and memory B cells 
The loss of DC-derived BAFF in CD16
-/-
 mice supports a role for CD16 in the memory 
response to NP14KLH.  To assess whether the diminished secondary response in CD16
-/-
 mice 
reflects a reduction in memory B cells, we assessed the frequency of NP-specific memory B cells 
(CD19
+
Ac38
+
IgG
+
) in B6 and CD16
-/-
 mice 28 days following immunization.  CD16
-/-
 mice 
showed a 2.4-fold decrease in the Ac38 Id
+
 IgG memory B cell population compared to 
immunized B6 mice (Figure 4D and 4E), indicating that CD16 regulates memory responses in 
part through BAFF production.    
Our data with immunized BAFF
-/-
 chimeras suggests that BAFF contributes to B cell 
memory by affecting the GC B and Tfh cell pool.  If the source of BAFF was exclusive to IgG-
ICs, then loss of CD16 would also diminish the GC B and Tfh pools. To assess this possibility, 
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we quantitated Tfh cells (CD4
+
CXCR5
+
PD-1
+
) from immunized B6 and CD16
-/- 
mice.  After 3 
days, CD16
-/-
 mice had a comparable frequency of Tfh cells compared to immunized B6 mice 
(Figure 4F).  However on day 7, CD16
-/-
 mice had 3-fold fewer Tfh cells, similar to the defects 
observed in immunized BAFF
-/-
 chimeras.  Adoptive transfer of BAFF transgenic, but not BAFF
-
/-
 BMDCs into immunized CD16
-/-
 mice, restored the frequency of Tfh cells on day 7 to levels 
seen in B6 mice (Figure 4G), suggesting that the defect was a consequence of reduced BAFF in 
CD16
-/-
 mice.  These findings demonstrate that CD16 ligation by IgG-ICs induces DCs to secrete 
BAFF and that CD16 is necessary for memory responses.  Together with the findings from the 
BAFF
-/-
 chimeras, our data suggest that IgG-IC binding to CD16 contributes to B cell memory 
through the effects of BAFF on Tfh cells and GC B cells.  
 
Loss of CD16 diminishes germinal center responses  
To assess whether loss of CD16 diminished GCs, we measured the frequency of splenic 
GC B cells (CD19
+
GL-7
+
CD95
+
) and Ac38 Id
+
 GC B cells 7 days after immunization.  We 
found that both subsets of GC B cells were significantly reduced in CD16
-/-
 mice (Figure 5A-C).  
Consistent with the diminished frequency of GC B cells, we found that the GCs in CD16
-/- 
mice 
were 54% smaller on day 7 post-immunization, but as the size of the B6 GCs declined (by day 
14 and 21) the sizes became similar (Figure 5D).  The smaller size of the CD16
-/-
 GC on day 7 
was not the result of delayed kinetics because by day 28, the GCs in both B6 and CD16
-/-
 mice 
were diminished, suggesting a comparable duration of the response (data not shown).  We also 
found that immunized CD16
-/-
 mice displayed a 2.3-fold reduction in the number of GCs on day 
7; however, the differences were less apparent on day 14.  By day 21, the CD16
-/-
 mice had a 
similar number of GC structures (Figure 5E).  Thus, although GCs form in the absence of CD16, 
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they are reduced in number and size early during the immune response. This suggests that 
stimulation of CD16 is an early event that impacts the GC response and subsequently, the 
memory B cell pool.   
 
CD16 and BAFF are required for the expression of Bcl-6 and the formation of GC and memory 
B cells 
Our data indicate that CD16 and ICs are required for DCs to make BAFF in response to 
NP-KLH (Figure 4A).  To address whether DC-derived BAFF was sufficient to restore the GC 
and memory B cell pools in the CD16
-/-
 mice, we adoptively transferred BMDCs from BAFF Tg 
mice at the time of immunization.  We found that BAFF Tg DCs restored the frequency of GC B 
cells on day 7 (Figure 6A), and the frequency of Ac38 Id
+
 memory B cells on day 28 (Figure 
6B).  In contrast, BMDCs derived from BAFF
-/-
 mice were unable to restore GC or memory B 
cells (Figure 6A and B), indicating that this effect was due to BAFF and not due to an increased 
number of DCs, or the secretion of other cytokines through activation of the transferred DCs.  
Since BAFF
-/-
 DCs have intact CD16, the results also emphasizes that BAFF, induced by CD16 
ligation, impacts the GC response and the frequency of memory B cells. 
Our data suggest that DC-derived BAFF acts at or upstream of Bcl-6 (Figure 1I, J, 2C, 
3A-C) and downstream of CD16 (Figure 4A).  Thus, the absence of CD16 should also 
diminished Bcl-6 during NP immunization and restoring DC-derived BAFF by BMDC transfer 
should restore Bcl-6 levels. To test this, we adoptively transferred BAFF Tg BMDCs into CD16
-
/-
mice at the time of immunization.  We found that compared to B6 controls CD16
-/-
 GC B cells 
expressed low levels of Bcl-6 after immunization.  Transfer of BAFF Tg BMDCs, but not BAFF
-
/- 
BMDCs, restored Bcl-6 levels in CD16
-/-
 GC B cells (Figure 6C). Thus, reduced BAFF due to 
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loss of CD16 impacts Bcl-6 expression in GC B cells and the effects were not influenced by 
changes in DC numbers or activation of transferred BMDCs. Collectively, the data show that 
IgG-ICs and CD16 induce BAFF production by DCs.  This suggests that BAFF acts upstream of 
Bcl-6 to induce the formation of GC B cells and to promote the maintenance of Tfh cells thereby 
promoting effective GC responses and B cell memory. 
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Discussion 
Interactions between T cells, B cells, and DCs are necessary for the proper execution of 
the adaptive immune response [141–143].  This study identifies a previously unappreciated 
mechanism for DCs, FcγRs, and BAFF in the early events of the GC response.  We show that 
ICs formed during the early IgG response to NP-KLH induced the production of BAFF by DCs.  
BAFF acted at, or upstream of, Bcl-6 to promote the optimal formation of GC B cells and in the 
stabilization of newly formed (day 7) Tfh cells. Loss of BAFF in hematopoietic cells, or loss of 
CD16, diminished the levels of Bcl-6, the frequencies of GC B cells, Tfh cells and memory cells, 
and the magnitude of the secondary antibody response. We found that DC-derived BAFF was 
sufficient to initiate these events.  This series of events depends on the formation of IgG-ICs, 
suggesting that productive early antibody responses contribute to the optimal formation of B cell 
memory.    
IgG-ICs and BAFF in the GC response 
ICs have previously been implicated in promoting adaptive immune responses through 
enhanced Ag presentation [144] and stimulating cytokine production by DCs [135,136]. We 
observed that IC ligation of CD16 was required for BAFF production by DCs after NP-KLH 
immunization. Although the loss of Fcγc reduces secondary antibody responses [62], it is not 
clear what role IC- FcγR interactions play in GC and memory B cell formation. Our data 
demonstrate that GCs and memory responses are disrupted in the absence of CD16 or when IC- 
FcγR interactions were blocked, indicating that FcγR signaling is important for these events. We 
also detected antigen-specific IgG by ELISpot within 2-3 days of immunization, making it 
possible for ICs to form and signal BAFF production before the initiation of GCs. This IgG was 
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likely secreted by class-switched extrafollicular PCs [140] that produce local levels of IgG early 
in the immune response [106,132,140].  
Although at day 7 of the primary response to NP-KLH, GCs, GC B cells, memory B cells 
and Tfh cells were diminished in the absence of FcγR-IC signaling, they were not completely 
absent and the numbers of GCs was increased on days 14 and 21. This suggests that signals other 
than BAFF, and perhaps other receptors for ICs are required for GC responses. We also observed 
incomplete loss of these populations after immunization of BAFF
-/-
 chimeric mice, suggesting 
DC-derived BAFF is only one of many signals required for optimal GC formation and function.  
Early in the adaptive immune response, B cells interact with cognate T cells and co-
stimulatory signals induce AID activation and class switch [145]. These signals include CD40L, 
which is also required for GC formation [146,147]. We found that BAFF
-/-
 chimeras had normal 
AID expression and primary IgG production, suggesting that cognate interactions mediated by 
CD40L were intact. Thus, BAFF likely acts downstream of initial T:B interactions. Our in vitro 
data show that recombinant BAFF directly induced Bcl-6 in activated B cells, and DC CM 
(elicited under conditions that induce BAFF) diminished the expression of XBP-1 and IRF-4.  
BAFF, therefore, may act on B cells after cognate T interaction, extinguishing the PC phenotype 
and either committing cells to the memory pathway or supporting the survival of GC B cell 
precursors. This is consistent with studies showing that DC secretion of the PC-inducing 
cytokine, IL-12, is dampened by IC signaling [148]. 
Another signal required for a productive GC reaction is IL-21. It is possible that BAFF 
acts in concert with IL-21 to induce and/or sustain expression of Bcl-6 in GC B cells [14,149]. T 
cell-secreted IL-21 acts on B cells both during initial T:B interactions and after GCs are formed 
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to promote either Blimp-1 or Bcl-6 expression, depending on the context [18], BAFF may serve 
as a contextual signal early in the adaptive response to direct B cells toward a GC fate. BAFF 
may also maintain Bcl-6 in B cells destined for the GC, allowing IL-21 from Tfh cells to take 
over as the response progresses. 
 
DCs as mediators of IC signaling 
Although DCs, MFs, and neutrophils are among the major producers of BAFF, [122,150–
154], our data support a role for DCs as the cells responsible for producing BAFF specifically in 
response to ICs after immunization. We found that transfer of BAFF-producing DCs, but not 
BAFF
-/-
 DCs, restored the numbers of GC B cells in BAFF
-/-
 chimeras and CD16
-/-
 mice.  This 
indicates that the defects in CD16
-/-
 mice were mediated through the loss of BAFF.  Further, 
BAFF-producing MFs were unable to restore the defects suggesting a unique role for DCs in this 
process consistent with tripartite interactions between DCs, T cells and B cells during adaptive 
immune responses. Other cells with Fc receptors may have roles similar to DCs that are worthy 
of further investigation. This current study indicates that DC-derived BAFF is sufficient to 
improve T-dependent GC responses and B cell memory. It also supports the use of DCs as a 
means to augment vaccine responses where better adjuvants are needed.   
 
BAFF and Tfh cells 
Previous studies showed that cells with a Tfh phenotype appear by day 3 after 
immunization [99,155,156].  These cells migrate towards follicles where they interact with B 
cells at the T-B border [156–159] to promote continuous expression of Bcl-6 
[103,105,134,158,160], and entry of Tfh cells into the GC [105,160,161].  Our data suggest that 
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B cells and IgG-ICs are not involved in the formation of Tfh cells (day 3).  This is consistent 
with previous studies showing that on days 1-3 post-immunization, the expression of Bcl-6 and 
CXCR5 in CD4
+
 T cells is independent of B cells [99,134,155].  Instead, BAFF acted 
downstream of the formation of Tfh cells, possibly to stabilize the population or promote its 
expansion.  Thus, previous studies showing a role for B cells in maintaining Tfh cells 
[109,155,158] might reflect the need for B cell-elicited Ig, ICs, and DC-derived BAFF.  The role 
of BAFF in maintaining the Tfh population may be indirect.  One possibility is that BAFF 
promotes the expression of ICOSL on B cells.  Previous studies showed that signaling through 
the BAFF-R regulates the expression of ICOSL on B cells [117,162], thereby sustaining 
interaction between Tfh cells and B cells at the T:B border and within GCs [99,100].  This 
interaction could also stabilize the expression of Bcl-6 and the downstream molecules CXCR5 
and PD-1[105,163,164] to maintain the “Tfh phenotype”.  This possibility is supported by 
studies showing that the absence of ICOSL on B cells reduces the frequency of CXCR5
+ 
CD4
+
 
cells after immunization [105], that ICOS:ICOSL interaction prolongs the engagement between 
B cells and Tfh cells [161], and that follicular bystander B cells support the formation and/or 
maintenance of Tfh cells by providing ICOSL in an antigen-independent manner [165].   
The interaction between GC B cells and Tfh cells is bidirectional.  Recent work described 
Tfh as a source of local BAFF within GC B cells that is required for affinity maturation [11].  
Tfh-derived BAFF, however, is not required for GC initiation or maintenance [11], and its role in 
memory B cell development remains unknown. Our work indicates that early production of 
BAFF is upstream of GC formation and memory B cell development. Interestingly, we observed 
a more complete loss of antigen-specific GC B cells (Ac38
+
) than total GC B cells in BAFF
-/-
 
chimeras and CD16
-/- 
mice. This may reflect a loss of local BAFF within the GC due to lack of 
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Tfh maintenance.  However, more work would be needed to determine whether affinity 
maturation is altered in these models.  
Overall, our studies highlight a novel role for IgG-ICs and DC-derived BAFF in the GC 
response.  Elucidating the events that initiate GC responses may impact our understanding of ICs 
and BAFF in autoimmunity.  Systemic lupus erythematosus (SLE) is an autoimmune disease 
characterized by elevated levels of BAFF, autoantibody/autoantigen ICs, and multi-organ 
pathology.  The formation of autoreactive memory is thought to be instrumental in driving long-
lived PCs and sustaining autoantibody production [166,167]; however, the mechanisms that 
regulate memory formation to self-antigens are unclear.  Our findings suggest that chronically 
high levels of ICs containing self-antigens could contribute to a break in B cell tolerance at the 
GC checkpoint.  In SLE, elevated levels of circulating ICs may elevate BAFF and promote the 
GC response [137,166,168–171].  This suggests that neutralization of BAFF in patients with SLE 
may affect both B cell survival and GC responses that are necessary in the formation of 
autoreactive memory cells [110,150,152,172]. 
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Materials and Methods   
 
Animals 
B6-Ly5.2 congenic mice were purchased from NCI, BAFF
-/-
 mice (Schiemann et al., 
2001), and CD16-2
-/- (FcγRIV) mice (Nimmerjahn et al., 2010) were obtained from, Glenn 
Matsushima, and Charles Jennette at UNC-Chapel Hill.  CD16
-/- 
and CD64
-/-
 mice (Hazenbos et 
al., 1996) were obtained from Dr. Anne Sperling at the University of Chicago, and BAFF Tg 
mice (Gavin et al., 2005) from Jeffrey Rathmell at Duke University.  CD32
-/-
 mice (Takai et al., 
1996) were purchased from Jackson labs.  Mice were used at 8-12 weeks of age and maintained 
in an accredited animal facility.  
Reagents and Antibodies 
Antibodies against mouse CD4, CD19, CD95, GL-7, ICOS, ICOSL, PD-1, and B220-647 
were purchased from Biolegend, CXCR5, B220, IgG1, IgG2a, IgG2b, and IgG3 antibodies from 
BD Biosciences, Bcl-6, XBP-1, and IRF-4 from Santa Cruz, and BAFF (1C9) from Enzo.  Anti-
μ F(ab)2 was purchased from Jackson ImmunoResearch.  Anti-μ (clone B7.6), anti-NP (clones 
H33L and B1-8), 2.4G2 (FcμRIIb/FcγRIII block) and Ac38 idiotype antibodies were purified 
from hybridoma supernatants.  (Ac38 is an idiotype antibody that recognizes B-1-8 specificities 
generated during NP immunization).  Recombinant mouse BR3-Fc and isotype control protein 
were generated using mammalian expression systems and standard purification protocols.  H33L 
and B1-8 were gifts from Dr. Garnett Kelsoe (Duke University).  IL-4 and IL-5 were purchased 
from Peprotech, recombinant BAFF (rBAFF) from R&D Systems, NP-OSu from Biosearch 
Technologies, KLH and PNA-biotin from Sigma Aldrich, alum from Thermo Scientific, and 
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streptavidin-Alexa 488 and Alexa 647 from Invitrogen.  Streptavidin-alkaline phosphatase and 
anti-IgG alkaline phosphatase were purchased from Southern Biotech. The Fc-binding TG19320 
peptide was synthesized as described (Fassina et al., 1998; Marino et al., 2000). 
B cell purification and bone marrow derivation of MFs and DCs  
Splenic B cells were isolated from B6 mice by negative selection (StemCell 
Technologies) and were 95-99% pure, as determined by flow cytometry.  Splenic DCs were 
purified by positive selection of CD11c
+
 cells (Miltenyi) from enriched low-density cells 
(OptiPrep; Sigma).  Purified cells were 80% CD11c
+
.  
Bone marrow-derived DCs (BMDCs) and bone marrow-derived MFs (BMMFs) were 
prepared from single cell suspensions from the tibias and femurs of B6, CD64
-/-
, CD32
-/-
, CD16
-/-
, and BAFF
-/-
mice. Following RBC lysis, cells were cultured 7 days in a 24 well low-cluster plate 
(Costar 3471) with 10 ng/ml GM-CSF and IL-4 to derive DCs and in 20 ng/ml M-CSF to derive 
MFs. 
Cell Culture  
We pre-formed immune complexes by stimulating B6 B cells (1.5 x 10
5
) with an excess 
of anti- (B7.6; IgG1; 30 μg/ml). The polyclonal IgM produced after seven days forms a 
complex with the excess anti- resulting in IgG1-IgM ICs in the supernatant.  These B cell 
supernatants were used as a source of ICs in preparing DC conditioned medium (DC CM).   
DC CM was prepared by culturing 2 x 10
4
 BMDCs (day 7) in a 96 well plate in the 
presence of IC-containing supernatants (see above; 20% of volume), IL-4 (25 ng/ml), and IL-5 
(25 ng/ml).  After seven days, supernatants were harvested and frozen at -80
o
C.    
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For in vitro co-cultures, 1.5 x 10
5
 purified B6 B cells were co-cultured with 1 x 10
4
 
BMDCs or ex vivo DCs in a 96 well plate stimulated with IL-4 (25 ng/ml), IL-5 (25 ng/ml) and 
30 μg/ml anti-μ with or without recombinant murine BAFF (5 ng/ml) or DC CM (20% of total 
volume).  Intracellular Bcl-6 was assessed by flow cytometry after 48 hours.  
ELISAs 
NP-specific IgG levels were quantitated from serum using microtiter plates coated with 
NP13BSA and blocked with 0.5% BSA.  Serially diluted serum samples were incubated 
overnight at 4
o
C.  Anti-NP was detected using an alkaline phosphatase conjugated rabbit anti-
mouse IgG antibody (1/1000 dilution) followed by phosphatase substrate.  Optical density (OD) 
values were converted to concentration based on standard curves using the H33L (anti-NP) 
hybridoma. 
ELISpot 
For the analysis of NP-specific B cells, multiscreen ELISpot plates (Millipore) were 
coated with NP13BSA in PBS and blocked with 1% BSA.  Single cell suspensions of spleen were 
prepared from immunized or naïve B6 mice.  After RBC lysis, cells were plated in serial 
dilutions on washed ELISpot plates. Anti-NP IgG-secreting spots were detected with anti-IgG-
biotin and streptavidin-HRP (BD Biosciences).  Plates were developed with 3-amino 9-
ethylcarbazole. 
To enumerate BAFF-secreting DCs, CD11c
+
 cells (1 x 10
6
) were purified from spleens 
and cultured for 60 hours on BR3-Fc coated ELISpot plates. BAFF-secreting cells were detected 
using anti-BAFF (clone 1C9).  To enumerate BAFF secreting cells from BMDCs, day 7 cells 
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(2.5 x 10
5
) were plated on ELISpot plates as above and incubated 24 hours with preformed ICs 
(IgM + anti-μ) prior to addition of 1C9.  Anti-μ ICs were made by combining the supernatant 
from stimulated B cells (20 ng of IgM) with anti-μ (5 μg).   In some experiments, TG19320 was 
added at 50 μg/ml to i  
Bone Marrow Chimeras 
B6-Ly5.2 congenic mice (6-8 weeks of age) were lethally irradiated (10.5 Gy; 1050 rads) 
and reconstituted with 8 x 10
6
 bone marrow cells from either B6 (B6 control chimeras) or  
BAFF
-/-
 (BAFF
-/-
 chimeras) mice.  After 8 weeks, we monitored reconstitution by assessing the 
frequency of CD45.1
+
 and CD45.2
+
 splenocytes by flow cytometry. 
Immunization and Adoptive Transfers of BMMF/BMDCs 
B6, BAFF
-/-
 bone marrow chimeras, and CD16
-/-
 mice (8-10 weeks of age) were 
immunized by intraperitoneal (i.p.) or subcutaneous (s.c.) injection with 100 μg of NP14KLH 
precipitated in an equal volume of alum (Imject® Thermoscientific).  Mice were boosted by 
intravenous (i.v.) injection with the same dose of soluble NP14KLH at day 35.  To assess the 
contribution of DCs or MFs in the secretion of BAFF, 8 X 10
6
 BAFF Tg or BAFF
-/-
 BMDCs or 
BMMFs were injected at the time of s.c. immunization.  Draining lymph nodes were harvested 
on day 7 for flow cytometry analysis. 
TG peptide injections 
B6 mice were immunized with 100 μg NP14KLH in alum (1:1) via i.p. injection and 
administered three (i.p.) injections (15-30 mg/kg) of Fc blocking peptide (TG19320) or equal 
amount of unrelated control peptide over the course of seven days. 
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Flow Cytometry 
GC B cells and Tfh were analyzed on day 7 post-immunization and were defined as 
CD19
+
, GL-7
+
, CD95
+
 and CD4
+
, CXCR5
+
, PD-1
+
.  Ac38 was used to define NP-specific GC B 
cells.  NP-specific memory B cells were defined as Ac38
+
 IgG
+
 double positive CD19+ 
lymphocytes. The lymphocyte gate was determined by forward and side scatter properties. To 
quantitate expression of intracellular IRF-4, Bcl-6 and XBP-1, splenocytes from immunized B6, 
CD16
-/-
, B6 control chimeras and BAFF
-/-
 chimeras mice were washed, fixed (4% 
paraformaldehyde), and permeabilized with methanol for a minimum of 24 hours at -20
o
C.  
Fixed cells were washed and FcγRIIb/FcγRIII blocked with 2.4G2 before staining.  Data are 
expressed as fold change in MFI/isotype control MFI. 
Real Time PCR  
Splenic B cells from B6 and BAFF
-/-
 chimeras were purified after NP14KLH 
immunization.  mRNA was isolated from 5-10 x 10
6
 purified B cells and  cDNA synthesized 
using Superscript VILO cDNA Synthesis Kit (Invitrogen).  DNA was subsequently amplified 
using FastStart Universal SYBR Green Master mix (Roche). Relative values were compared 
using the 2
-ΔΔCΤ
 method. 18s rRNA was used as an internal control in all experiments.  Primers 
included:  murine Aicda forward 5’GGGAAAGTGGCATTCACCTA3’, murine Aicda reverse 
5’GAACCCAATTCTGGCTGTGT3’ murine 18s rRNA forward 
5’TCAAGAACGAAAGTCGGAGGTT3’, murine 18s rRNA revese 5’-
GGACATCTAAGGGCATCACAG-3’. 
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Germinal Center Staining and Counting 
Spleens were harvested from B6 or CD16
-/-
 mice on days 7, 14, and 21 after 
immunization and flash frozen in OCT (Optimum Cutting Temperature; Fisher).  Tissue sections 
(6 micron) were fixed in 1:1 MeOH/Acetone, blocked with 10% FBS in PBS containing 2.4G2, 
and stained with PNA-biotin and B220-Alexa647, and Streptavidin-Alexa488.  Germinal centers 
were defined as PNA
+
 cell clusters within B220
+
 follicles (Han et al., 1997). The number of 
germinal centers per mm
2
 of B220
+
 area was determined by dividing the number of germinal 
centers counted in a field by the area of B220
+
 follicles in the same field.  This accounted for 
follicles that were only partially represented in a given field (Holl et al., 2011). This was done for 
10-30 fields per mouse, totaling 30-100 follicles per mouse at each time point.   
Microscopy 
Macroscope images were obtained on a Leica MX16FA fluorescence stereo 
microscope/macroscope (0.63x objective; numerical aperature of 1.0).  Other images were 
obtained using an Olympus Fluoview 500 (10x objective; numerical aperature of 0.45). 
Statistics 
The one-sided, or one-sample t test was used to compare changes in transcription factor 
levels and in vitro cytokine and antibody secretion to control values.  Two-sample student’s t 
tests were used to assess statistical differences between cell populations measured by flow 
cytometry and ELISpot, and for serum antibody secretion on days 42 and 49. Analyses were 
performed in GraphPad Prism. 
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Table 2. 1 Mice used for Chapter 2 
 
Mouse line Description 
C57BL/6 (B6) Wild-type 
B6 Chimera Lethally irradiated B6 reconstituted with 
congenic B6 bone marrow 
BAFF
-/-
 Lacks BAFF 
BAFF
-/- 
Chimera Lethally irradiated B6 reconstituted with 
congenic  BAFF
-/- 
bone marrow 
CD16
-/-
 Lacks FcγRIII 
BAFF Tg Constitutively expresses BAFF in Myeloid 
cells 
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Chapter 2 Figures 
 
Figure 2. 1 BAFF
-/-
 chimeras have defective memory and GC B cells, diminished Bcl-6 levels 
and decreased frequency of Tfh cells.   
 (A) B6 and BAFF
-/-
 chimeric mice were immunized (i.p) with 100 g NP14KLH in alum.   
Serum IgG anti-NP responses in B6 and BAFF
-/-
 chimeric mice were measured by ELISA on 
days 7, 14, 21, 28, and 35 post immunization.  n=4-6 mice per group over 3 experiments.  (B) 
Serum IgG anti-NP levels measured on days 39, 42, and 49 (4, 7, and 14 days) following boost 
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of 100 g of soluble NP14KLH on day 35.  n = 3-6 mice over 3 experiments.  (C) CD19
+
Ac38
+
 
IgG
+
 B cells enumerated by flow cytometry from the spleens of B6 and BAFF
-/-
 chimeras 
immunized for 28 days.  n = 4-6 mice over 4 experiments.  (D and E) CD4
+
CXCR5
+
PD-1
+
 T 
cells from B6 and BAFF
-/- 
chimeric mice enumerated on days 0, 3 and 7 following 
immunization.  n = 3-6 mice per time point over 2 experiments.  (F and G)  CD19
+
, GL-7
+
, 
CD95
+ 
GC
 
B cells enumerated by flow cytometry on day 7 post-immunization.  n = 3-5 mice 
over 3 experiments.  (H) CD19
+
Ac38
+
CD95
+
GL-7
+
 B cells enumerated on day 7 post-
immunization.  n = 3-5 mice over 3 experiments.  (I and J) Relative expression of Bcl-6 in GC B 
cells (CD19
+
CD95
+
GL-7
+
) from B6 and BAFF
-/- 
chimeras measured 7 days after NP14KLH 
immunization (i.p.).  n = 4-6 mice per group over 2 experiments.  ** p ≤ 0.01, *p ≤ 0.05, n.s. = 
not significant         
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Figure 2. 2 Secretion of BAFF by DCs restores Bcl-6 levels and the frequency of GC B and Tfh 
cells.   
(A-C)  BAFF Tg BMDCs, BMMFs, or BAFF
-/-
 BMDCs (8 x 10
6
) were injected (s.c.) into B6 or 
BAFF
-/- 
chimeric mice that were simultaneously immunized (s.c.) with NP14KLH.  On day 7, 
inguinal lymph nodes were harvested and the frequencies of (A) GC B cells (GL-7
+
CD95
+
 cells 
in CD19
+ 
B cells), (B) Tfh cell (CXCR5
+
PD-1
+
 cells in CD4
+
 T cells), and (C) Bcl-6 expression 
in GC B cells from inguinal lymph nodes was measured by flow cytometry.  n = 3-5 over 3 
experiments. (D) On days 2, 3, and 7 following immunization, 1 x 10
6
 splenocytes from B6 mice 
were plated on NP-BSA-coated ELISpot plates.  After 18 hours, NP-specific ASCs were 
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quantitated.  n = 3-4 mice per time point over 3 experiments.  (E) 1 x 10
6
 purified CD11c
+
 cells 
from B6 mice immunized for 2, 3, and 7 days were plated on BR3-Fc coated ELISpot plates.  
After 60 hours, the number of BAFF secreting cells was enumerated.  n = 3-6 mice per time 
point over 3 experiments.  (F) BAFF secreting cells enumerated from B6 BMDCs (2.5 x 10
5
) 
cultured for 24 hrs in the presence or absence of anti-μ ICs, with or without Fc blocking peptide 
(TG19320; 50 μg/ml).  n = 3-10 over 6 experiments.  (G-H) B6 mice were immunized with 
NP14KLH and dosed with 15-30 mg/kg of Fc blocking peptide (TG19320) or an unrelated 
scrambled peptide (Control) via i.p. injection.   On day 7, the frequency of Tfh cells 
(CD4+CXCR5+PD1+, G) and GC B cells (CD19+GL7+CD95+, H) was determined. n = 3-6 
over 2 experiments. **p ≤ 0.01, *p ≤ 0.05, n.s. = not significant   
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Figure 2. 3  DC-derived BAFF regulates the expression of Bcl-6 in cultured B cells.   
Purified B6 B cells (1 x 10
5
) stimulated with anti-μ (30 μg/ml), IL-4 (25 ng/ml), and IL-5 (25 
ng/ml) were co-cultured with DC CMs. Intracellular levels of key transcription factors (Bcl-6, 
XBP-1, IRF-4) were measured by flow cytometry on day 2.  (A) Bcl-6 expression in B cells co-
cultured with B6 DC CM or rBAFF (5 ng/ml).  (B) Representative histogram of Bcl-6 expression 
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in B cells activated by DC CM as in (A).  n = 3-4 mice over 4 experiments. (C) Purified B6 B 
cells were co-cultured with CM generated from B6 DCs treated with ICs containing intact Fc 
regions (B6 DC CM), F(ab’)2 (B6 DC CM (Fab’)2), BAFF
-/-
 DC CM, or B6 DC CM neutralized 
with BR3-Fc (10 μg/ml) or control IgG-Fc (10 μg/ml).  n = 4-7 over 4 experiments.  (D-G) B 
cells were co-cultured with B6 DC CM.  Intracellular levels of XBP-1 (D, E) and IRF-4 (F, G) 
were quantitated.  n = 3 mice per group over 3 experiments.  Histograms are representative of 3 
experiments.  (H) Bcl-6 expression in B cells cultured with DC CM from B6, CD64
-/-
, CD32
-/-
, 
CD16
-/-
, or CD16-2
-/-
 (FcγRIV) mice.  n=6-7 mice per group over 4 experiments.  p ≤ 0.01, * p ≤ 
0.05, n.s. = not significant.   
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Figure 2. 4 CD16
-/-
 mice have defective BAFF secretion, secondary antibody responses, 
frequency of memory B cell and Tfh cells.   
(A) BAFF secreting cells enumerated from purified CD11c
+
 cells isolated from B6 and CD16
-/-
 
mice on day 7.  n = 3 over 3 experiments.  (B and C) B6 and CD16
-/-
 mice were immunized (i.p) 
with 100 g NP14KLH in alum.   Serum IgG anti-NP (B) primary responses measured by ELISA 
on days 0, 7, 14, 21, 28, and 35; serum IgG (C) secondary antibody levels measured on days 39, 
42, and 49 (days 4, 7, and 14) following boost of 100 g soluble NP14KLH on day 35.  n = 4-8 
mice over 3 experiments.  (D and E) CD19
+
Ac38
+
IgG
+
 memory B cells enumerated by flow 
cytometry from the spleens of B6 and CD16
-/-
 mice immunized for 28 days.  n = 5-6 mice over 3 
experiments.  Data are expressed as the percent of CD19
+
 cells that are IgG
+ 
and Ac38
+
.  (F) The 
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frequency of CD4
+
CXCR5
+
PD-1
+
 T cells from immunized B6 and CD16
-/-
 mice on days 0, 3 or 
7.  n = 3-8 mice per time point over 4 experiments.  (G) B6, BAFF Tg, and BAFF
-/-
 BMDCs (8 x 
10
6
) were injected into CD16
-/-
 mice that were simultaneously immunized with NP14KLH.  On 
day 7, the frequencies of CD4
+
CXCR5
+
PD-1
+
 T cells from inguinal lymph nodes were 
enumerated by flow cytometry.  n = 3-7 mice over 3 experiments.   p ≤ 0.01, *p ≤ 0.05, n.s. = not 
significant   
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Figure 2. 5  CD16
-/-
 mice have diminished germinal center responses.  
(A and B) The frequency of splenic CD19
+
GL-7
+
CD95
+ 
GC B cells was measured by flow 
cytometry from B6 and CD16
-/-
 mice 7 days after immunization. n = 4-11 mice per group over 3 
experiments.  (C) The frequency of NP-specific GC B cells (CD19
+
Ac38
+
GL-7
+
CD95
+
) 
measured in B6 and CD16
-/-
 mice 7 days after immunization.  n = 3-10 mice over 3 experiments. 
(D) The size of GCs and (E) the number of GCs were enumerated from B6 and CD16
-/-
 mice 7, 
14, and 21 days after immunization using confocal microscopy.  n = 3-6 mice per time point over 
4 experiments.   
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Figure 2. 6  Adoptive transfer of BAFF expressing DCs rescues GC and memory B cell 
populations and restores Bcl-6 levels in CD16
-/-
 mice B cells.    
(A) BMDCs (8 x 10
6
) from BAFF Tg or BAFF
-/-
 mice were injected (s.c.) into CD16
-/-
 mice and 
simultaneously immunized (s.c.) with NP14KLH.  On day 7, the percentage of GC B cells 
(CD19
+
GL-7
+
CD95
+
) were measured from inguinal lymph nodes.  n = 3-7 mice per group over 3 
experiments.  (B) Same as (A) but on day 28, CD19
+
Ac38
+
IgG
+
 memory B cells were 
enumerated.  n = 3-4 over 2 experiments.  (C) BAFF Tg, and BAFF
-/-
 BMDCs (8 x 10
6
) were 
injected into CD16
-/-
 mice and simultaneously immunized with NP14KLH.  n = 4 mice over 3 
experiments. On day 7, Bcl-6 expression in GC B cells from inguinal lymph nodes was measured 
by flow cytometry.   **p ≤ 0.01, *p ≤ 0.05, n.s. = not significant. 
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Figure 2. 7 Chapter Two Model.  
During an adaptive immune response (in this example, to NP-KLH), B cells respond to BCR 
ligands and co-stimulation by differentiating into short-lived plasma cells that secrete IgG. IgG 
binds antigen and forms IC’s that signal DCs to make BAFF by binding FcγR (in the case of NP-
KLH, FcγRIII). Before and/or during the germinal center reaction, BAFF signals B cells directly 
or indirectly to upregulate Bcl-6, a transcription factor required to maintain germinal center B 
cells and form memory B cells.  
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CHAPTER 3: Staphylococcus aureus Protein A Disrupts Immunity Mediated by Long-Lived 
Plasma Cells
2
 
 
Introduction 
 
Staphylococcus aureus is a major cause of hospital and community acquired infections 
and has become more difficult to treat as antibiotic-resistant strains spread [72–74].  S. aureus 
infections commonly recur without inducing long-term immunity [67,68].  Attempts to design a 
human vaccine have failed despite the ability of some vaccine approaches to induce short-term 
protection in mouse models [173–180].  Sustained serum antibody is key for conferring long-
term protection against infection.  Antibodies against S. aureus enhance phagocytosis of the 
bacteria, block adhesion, and prevent abscess formation in mice [179,181,182].  In humans, high 
levels of pre-existing antibody are associated with reduced incidence of infection [64–66]. 
However antibody levels wane unpredictably, leading to the loss of vaccine efficacy [69–71].  
This suggests that S. aureus disrupts the longevity of the humoral immune response.    
Memory B cells and LLPCs are two cell types that confer long-term humoral immunity.  
Serum antibody levels are sustained by LLPCs that are derived mainly from memory B cells 
activated during secondary immune responses [33–37].    Memory B cells have been identified 
                                                          
2 Amanda B. Keener, Lance T. Thurlow, Nicholas A. Spidale, Steven H. Clarke, Kenji M. Cunnion, 
Roland Tisch, Anthony R. Richardson, Barbara J. Vilen (2014) Staphylococcus aureus Protein A 
Disrupts Immunity Mediated by Long-Lived Plasma Cells (Unpublished data). 
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after infection with viral, parasitic, and bacterial pathogens [183–186], but whether these cells 
are formed after S. aureus infection has not been addressed.  Memory B cells reside in an 
inactive state in the secondary lymphoid organs, and upon re-exposure to antigen, rapidly divide 
into daughter cells or differentiate into immature ASCs called PBs (CD138
+
, B220
lo/neg
, Ig
+
) 
[32,187].    
The majority of PBs become short-lived PCs (CD138
+
, B220
lo/neg
, Ig
-
); however, some 
migrate to survival niches in the BM and mature into LLPCs [33,37,188].  LLPCs and their 
constitutively secreted antibody are now recognized as major contributors of protection against 
bacterial infection [35,44,49].  LLPCs can survive at least 100 days [43] and up to the lifetime of 
the organism [36,40].  In humans, LLPC survive for months to decades and are the main source 
of convalescent serum IgG [36,40,189,190].  Recent work has revealed a relationship between 
long-term antibody maintenance and resistance to recurring S. aureus infections [63], yet it 
remains unknown whether LLPCs are formed after S. aureus infection.   
The factors that deter long-lasting immunity to S. aureus are not completely understood.  
The complex array of S. aureus virulence factors and surface proteins promote evasion from the 
adaptive immune response [76,191,192]. SpA is a virulence factor that directly modulates the B 
cell response [75,82].  SpA has five Fc-binding domains that sequester IgG and interfere with 
immune complex (IC)-mediated antigen presentation and phagocytosis [77–79].  SpA also 
activates B cells upon binding the F(ab) portion of B cell receptors of the VhIII clan (up to 50% 
of naïve B cells in humans and 5-10% in mice) [80,81].  In the context of infection, this binding 
enhances secretion of SpA-specific IgM [193].  Immunization with a mutant SpA that cannot 
bind either the Fc or Fab regions of Ig induces neutralizing anti-SpA antibodies that protect mice 
from sepsis and lead to an enhanced and more diverse antibody response [84,194].  This suggests 
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that the presence of SpA on S. aureus alters the B cell response to infection.  However, whether 
SpA influences long-term B cell memory, or LLPCs has not been addressed.   
In this study, we show that SpA disrupts BM accumulation of LLPC by enhancing the 
short-lived ASC response.  Previously inoculated mice that were challenged with a SpA-
deficient S. aureus mutant (Δspa), but not with WT S. aureus, formed LLPCs and maintained 
serum antibody for at least 12 weeks after challenge.  The lack of long-term humoral immunity 
to WT S. aureus was not due to defects in memory B cell formation or activation because 
primary infection with either WT or Δspa induced the formation of germinal centers and 
functional memory B cells.  Rather, SpA altered the differentiation of ASCs during the 
secondary response by expanding IgM
+
 extrafollicular PBs, disrupting the LLPC compartment, 
and preventing long-term antibody maintenance. 
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Results  
 
The primary and secondary antibody responses to S. aureus are unaffected by Protein A. 
A successful adaptive immune response results in immunological memory that confers 
long-term protection during subsequent exposure.  To assess whether S. aureus induces the 
formation of memory B cells, and whether this was impacted by Protein A (SpA) we 
subcutaneously inoculated mice with strain RN4220 expressing SpA (WT), or an isogenic spa 
mutant (Δspa).  We chose subcutaneous inoculation for the primary response because clearance 
of S. aureus could be readily monitored at the injection site.  We found that infection was cleared 
within 3 weeks and the mild virulence of RN4220 allowed inoculated mice to be analyzed over a 
long period of time without significant weight loss, morbidity, or depletion of B cells 
(Supplemental Figure 1A).  To characterize the primary immune response, we measured the 
total S. aureus-specific IgG and IgG2 over time (Figure 1A).  A modest level of IgG2 (Figure 
1B) and total IgG (Supplemental Figure 1B) was detectable between 2 and 5 weeks after 
primary inoculation regardless of whether mice were inoculated with S. aureus Δspa (1.5-fold) 
or WT (2-fold). 
The increase of S. aureus-specific IgG between the first and second weeks after primary 
inoculation suggested that a T-dependent immune response had induced class switch.  GCs are 
the sites of class switching and affinity maturation, and are required for the formation of high-
affinity memory B cells [9,130,195].  To define whether S. aureus induced GCs, we quantitated 
GC B cells over the course of the primary response. Subcutaneous inoculation with S. aureus 
RN4220 Δspa or WT induced GC B cells in the draining lymph nodes and spleen with similar 
kinetics, peaking between days 7 or 14 and resolving by day 35 (Figures 1C-D).  Tfh cells, 
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which are required for GC development [3,95] were also induced in similar frequencies after 
primary inoculation with S. aureus Δspa or WT (Supplemental Figure 1C).   
One possible mechanism underlying the lack of long-term immunity to S. aureus is 
failure to promote the formation of memory B cells.  We used ELISpot to indirectly detect the 
numbers of S. aureus antigen-specific memory B cells after in vitro polyclonal stimulation as no 
flow cytometry methods are available.   IsdB was chosen as the target antigen since anti-IsdB 
IgG has been detected in infected mice, and has recently been studied in vaccination trials 
[84,173,196].  On day 35 post-inoculation, ex vivo lymphocytes from the spleens and lymph 
nodes were polyclonally activated with pokeweed mitogen.  The 6-day culture period is too short 
to induce class-switch, thus all antigen-specific IgG-secreting cells detected by ELISpot were 
derived from memory B cells [183,184,189].  We detected significantly greater numbers of class-
switched IsdB-specific ASCs in both Δspa and WT-inoculated mice compared to naïve mice 
(Figure 1E), suggesting that memory B cells were formed as a result of infection in the presence 
or absence of SpA.  Together these data suggest that the lack of long-term protection against S. 
aureus is not due to failure to form memory B cells. 
Another possibility is that memory B cells develop normally, but fail to be reactivated 
upon re-infection.  Memory B cell responses are more rapid and robust than primary responses to 
the same stimuli [1,22,197].  To test whether memory B cells are activated upon secondary 
exposure to S. aureus, we inoculated mice a second time (herein referred to as challenge) and 
measured antibody responses.  We challenged mice intravenously (IV) with S. aureus RN4420 
WT or Δspa to mimic sepsis conditions, and measured antibody responses over two weeks 
(Figure 1A).  Challenge of previously inoculated mice resulted in amnestic (2-6 fold) IgG and 
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IgG2 responses whether the primary inoculation was WT or Δspa (Figure 1F and 
Supplemental 1D).   
To ensure that the enhanced and rapid IgG response induced by IV challenge was 
dependent on previous infection rather than initiating a new primary response, we compared IgG 
and IgG2 responses on day 49 (14 post-challenge) to those produced 14 days after a primary IV 
infection.  Consistent with memory cell activation IV challenge of previously inoculated mice 
induced significantly higher levels of IgG2 and IgG compared to naïve mice (Figure 1G and 
Supplemental 1E).  In addition, we found that challenge with either WT or Δspa S. aureus 
induced amnestic IgG responses to IsdB (Figure 1H), that were also dependent on previous 
infection (Figure 1I).  To ensure that the secondary response was not unique to RN4220, we 
subcutaneously inoculated and IV challenged mice with the clinical strains, Newman and 
USA300.  We observed enhanced secondary responses similar to those induced by RN4220 
(Supplemental Figure 1F).  
A hallmark of memory B cells is their longevity [21].  It is possible that the memory B 
cells formed after S. aureus infection are not long-lived, thus diminishing long-term immunity.  
To assess this, we challenged mice 100 days after primary inoculation and found that challenge 
with WT or Δspa induced an amnestic S. aureus-specific antibody response (2-3 fold) (Figure 
1J).  It is also possible is that failure of memory B cells to self-renew after repeated challenge 
contributes to the lack of long-term protection against S. aureus.  To examine this, we challenged 
mice a second time (third infection) 6 weeks after the first IV challenge.  The second challenge 
boosted antibody production (Figure 1K), indicating memory B cells were not depleted or 
rendered unresponsive. Together these data indicate that regardless of the presence or absence of 
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SpA, long-lived memory B cells are formed and activated after S. aureus inoculation and 
challenge.       
 
The presence of Protein A during challenge preferentially expands plasmablasts  
 
When memory B cells are activated, they rapidly divide, forming antibody-secreting PBs 
(CD138
+ 
B220
lo/neg 
surface Ig
+
) that mature into plasma cells (PCs) (CD138
+ 
B220
neg 
surface Ig
-
) 
[22,24,32,33,198].  To assess whether SpA impacted the PC response, we enumerated PBs and 
PCs (collectively referred to herein as ASCs) [199].  Mice challenged (IV) with either WT or 
Δspa S. aureus made more total ASCs compared to naïve mice given a primary IV infection 
(Figure 2A-C and Supplemental Figure 2A).  However, the frequencies and numbers of total 
splenic ASCs were significantly higher after WT challenge.  This expansion was induced by WT 
challenge regardless of whether mice were initially inoculated with WT or Δspa (Figure 2B-C 
and Supplemental Figure 2A), and was unrelated to changes in total CD19
+
/B220
+
 B cells 
(Supplemental Figure 2B).  
SpA has previously been identified as a B cell superantigen that binds the VhIII class of 
BCRs and drives polyclonal B cell expansion and apoptosis [75,82].  SpA is released from S. 
aureus during normal cell division, making it possible for the protein to reach B cells in the 
spleen in soluble form and through DC-mediated presentation during the course of an infection 
[200–202].  IgM binds SpA with a higher affinity than IgG [203], so we reasoned that if SpA 
drove ASC expansion by binding F(ab)s, the ASC population would predominately be PBs that 
retained surface IgM [6].   We found that 54% of the ASCs formed after WT challenge retained 
surface IgM whereas 30% of ASCs formed after Δspa challenge retained surface IgM (Figure 
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2D).  The frequency of ASCs retaining IgG was not significantly different between the two 
groups (20.5% of Δspa and 17.8% of WT) (Figure 2E). These data indicate that most of the 
expanded ASCs were derived from IgM
+
 cells suggesting they were induced through the F(ab)-
binding activity of SpA.   
To assess whether expansion of IgM
+
 cells impacted the antigen-specific IgG response, 
we quantitated the class-switched IsdB-specific ASC response by ELISpot on day 40 (day 5 
post-challenge) (Figure 2A).  Consistent with a memory response (Figure 1E), we found that 
mice challenge with S. aureus RN4220 Δspa or WT, produced 2-6 times more IsdB-specific IgG 
ASCs than naive mice that were inoculated IV on the same day; however, the numbers of IsdB-
specific ASCs did not differ between mice challenged with WT versus Δspa (Figure 2F).  
Collectively, these data suggest that long-lived, memory cells are formed regardless of whether 
mice are inoculated with WT or Δspa S. aureus.  Upon reactivation, the newly formed PCs 
produce comparable amounts of antigen-specific IgG antibody; however, challenge with WT S. 
aureus promotes a robust expansion of IgM
+
 PBs.  
SpA is a known virulence factor of S. aureus and kidney bacterial load is reduced after 
infection with S. aureus Δspa compared to WT [204–206].  Thus, it is possible that the reduced 
virulence of Δspa limits the expansion or IgM+ PBs [207,208].  To test this, we challenged mice 
with S. aureus Newman WT, Δspa, or ΔsrrAB, a mutant that expresses SpA but displays a 
virulence defect similar to that of Δspa (Supplemental Figure 3A).  Challenge with S. aureus 
ΔsrrAB induced expansion of IgM+ PBs similar to that seen after WT challenge (Supplemental 
Figure 3B-C).  Thus, the lack of expansion of IgM
+ 
PBs was not caused by reduced virulence, 
but was specifically related to the absence of SpA.  
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The presence of Protein A during challenge enhances the short-lived extrafollicular response  
IgM
+
 ASC responses are typically short-lived [8,38,39].  To determine whether the 
expanded ASCs induced by SpA were short-lived, we monitored CD138
+ 
B220
lo/neg
 cells by flow 
cytometry over the course of two weeks. We found that the frequencies and number of ASCs 
peaked in the spleens of both WT and Δspa-challenged mice on day 40 (day 5 post-challenge) 
and declined by day 42 (day 7 post-challenge) (Figure 3A).  This is consistent with the expanded 
PB population consisting mainly of short-lived cells.     
Short-lived responses are typically extrafollicular [30,209,210], so to examine whether 
the ASC expansion induced by WT challenge was extrafollicular, we first examined splenic 
DCs,  which are key mediators of extrafollicular responses that carry intact antigen into 
lymphoid organs and produce cytokines conducive to PB differentiation [201,202,211–213].  We 
analyzed the frequencies of classical and plasmacytoid DC subsets and their expression of 
surface markers associated with activation (CD80, CD86, MHCII, CD11c and CD40).  We found 
no significant differences in the DC populations induced by WT or Δspa challenge (data not 
shown).  TLR2 ligands expressed during S. aureus infection induce DCs to make IL-12, a 
cytokine that promotes ASC differentiation [197,214–217]. IL-12+ DCs are expanded in 
immunized Fcγ-/- mice, indicating a role for immune complexes (ICs) in regulating DC IL-12 
[148].  Because IC binding to FcγRs is impeded by SpA’s Fc-binding function, we quantitated 
IL-12-producing CD11c
+ 
DCs on day 40 (day 5 post-challenge).  We found that WT and ΔsrrAB 
challenge induced 1.7-fold more IL-12
+
 DCs than Δspa challenge (Figure 3B and 
Supplemental Figure 3D).  This suggests that SpA binding to the Fc region of Ig could play a 
role in PB expansion by promoting DC IL-12.   
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Expansion of IL-12
+ 
DCs is associated with enhanced short-lived extrafollicular 
responses [148].  To determine whether the expanded IgM
+
 PBs represented an extrafollicular 
response, we analyzed spleen sections on day 40 (day 5 post-challenge).  WT challenge resulted 
in larger and more frequent extrafollicular foci composed of IgM
+/bright
 cells compared to Δspa 
challenge (Figure 3C).  These foci were located mainly in the red pulp of the spleen (3C 
arrows) and could be identified in bridging channels next to B cell follicles (Figure 3C 
asterisks).  
 
ASCs fail to populate the bone marrow following challenge with WT S. aureus 
Activation of memory B cells promotes the formation of ASCs that migrate to sites of 
inflammation, or to survival niches in the bone marrow (BM) where they constitutively produce 
protective IgG [33,43].  Expansion of splenic ASCs is observed in models of autoimmunity or in 
chronic inflammation where migration to, or retention in, the BM is disrupted by chronic 
production of short-lived PCs [207,218–220], defective migration to the BM [34], disruption of 
the BM PC niche [34,41] or a combination of these effects.  Since challenge with WT S. aureus 
expanded extrafollicular short-lived PBs, we examined whether this expansion disrupted the 
establishment of long-lived PCs (LLPCs) in the BM.   
The majority of antigen-specific PCs migrate to the BM within 2 weeks of forming [35–
37]. Therefore, we measured IsdB-specific IgG ASCs from the spleen and BM by ELISpot on 
day 49 (day 14 post-challenge).  We observed significantly more IsdB-specific IgG ASCs in the 
BM of mice challenged with Δspa compared to mice challenged with WT S. aureus (Figure 4A 
and B).  These BM ASCs likely derived from activated memory cells since the number of ASCs 
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present on day 49 (day 14 post-challenge) were significantly higher than the numbers present in 
the BM 14 days after primary IV Δspa infection.  This indicates that SpA interferes with the 
accumulation of BM ASCs derived from memory B cells during challenge. 
The activation of memory B cells during challenge initiates GC reactions [23,25,185].  In 
many cases, expansion of short-lived extrafollicular ASCs occurs at the expense of GC 
formation; a critical event in the formation of LLPCs  [10,48,190,221,222]. To assess this 
possibility, we quantitated the frequency of GC B cells during the course of the secondary 
response and found that GC B cells expanded after challenge with either Δspa or WT (Figure 
4C).  Although the frequency of B cells that were positive for GL7 and Fas was higher after WT 
challenge on day 40 (day 5 post-challenge), the total numbers of GC B cells were not 
significantly different at this time point (Supplemental Figure 4A).  By microscopy, GC 
structures of similar sizes were detected after Δspa and WT challenge at similar frequencies and 
T-B architecture was not disrupted (Supplemental Figure 4B).  Therefore, defective 
accumulation of BM ASCs after WT challenge was not caused by the inability to form secondary 
GCs.   
 
Bone marrow ASCs do not accumulate after WT challenge despite normal migration and 
adequate niche factors 
To determine whether SpA affected the kinetics of the ASC migration to the BM, we 
quantitated CD138
+
B220
lo/neg
 ASCs in the BM during the first 3 weeks after challenge.  We 
found no increase in BM ASC numbers 35 days after primary subcutaneous inoculation with S. 
aureus RN4220 Δspa or WT (Figure 5A), consistent with reports that higher numbers of LLPCs 
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are formed during secondary responses than after primary responses [32,36].  ASCs appeared in 
the BM by day 40 (day 5 post-challenge) regardless of whether mice were challenged with WT 
or Δspa S. aureus (Figure 5A); however, the number of BM ASCs declined in the WT-
challenged mice after day 45 (day 10 post-challenge).   Conversely, ASC numbers continued to 
rise in the Δspa-challenged mice.  By day 49 (day 14 post-challenge) the Δspa-challenged mice 
displayed significantly higher frequencies and numbers of BM ASCs than mice challenged with 
WT or ΔsrrAB (Figure 5A, Supplemental Figure 5A).   
Surface expression of CXCR4 guides ASCs toward CXCL12 emanating from the BM 
[51].  Since SpA induces internalization of CXCR4 in vitro [223], alterations in CXCR4 
expression or responsiveness after WT challenge could disrupt homing of ASCs to the BM.  To 
assess this, we quantitated surface CXCR4 on ASCs on day 40 (peak response; day 5 post-
challenge), when ASC start to migrate from the spleen.  We found that the levels were not 
different regardless of whether mice were challenged with S. aureus WT or Δspa (Figure 5B).  
Consistent with comparable expression, ASCs from WT and Δspa challenge mice showed 
comparable migration toward CXCL12 (SDF-1) through a trans well membrane (Figure 5C).  
The presence of SpA in the challenge infection, therefore, did not appear to inhibit initial 
migration of ASCs to the BM, but rather impacted their accumulation 2 weeks after challenge.   
Systemic inflammation can make the BM microenvironment inhospitable to LLPCs by 
depleting niche factors including eosinophils and APRIL [34,50,56].  It is possible that SpA 
disrupted these niche factors during WT infection, preventing LLPCs from establishing in the 
BM. We analyzed these factors on day 40 (day 5 post-challenge) at which point, eosinophils 
peak in the BM [55]. The frequencies and numbers of eosinophils and APRIL
+ 
BM cells were 
similar between WT and Δspa-challenged mice (Figure 5D-E and Supplemental Figure 5B). 
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This suggests that the defect in PC accumulation after WT challenge was not caused by the loss 
of niche factors known to be disrupted by inflammation [188].   
To confirm that the BM microenvironment was competent to support LLPCs, we 
assessed whether ASCs of a different specificity could populate the BM during WT or Δspa S. 
aureus infection.  We immunized mice with (4-hydroxy-3-nitrophenyl)-acetyl hapten conjugated 
to Keyhole limpet hemocyanin (NP-KLH), and 35 days later boosted mice with NP-KLH alone 
or co-infected IV with S. aureus RN4220 WT or Δspa.  We detected NP-specific IgG ASCs in 
the BM on day 49 (day 14 post-boost) at similar frequencies regardless of whether mice were co-
infected with WT or Δspa (Figure 5F).  This indicates that the BM niche was intact after IV 
infection with S. aureus.  Collectively, these data indicate that the lack of BM PC accumulation 
after WT challenge was not caused by a disruption in the BM niche environment, but by an 
alteration in the ASC population itself.  Consistent with this, ASCs present in the BM of WT-
challenged mice displayed significantly reduced levels of APRIL receptor and maturation 
marker, CD138 (Supplemental Figure 5C), indicating a less mature phenotype than ASCs 
induced in the absence of SpA [46,47].   
 
Protein A prevents long-term maintenance of antigen-specific IgG by bone marrow plasma cells 
Although the BM is the main site of LLPC survival, the spleen also harbors PCs for a 
significant period of time [220,224].  We examined whether expanded ASCs induced by WT 
challenge would persist in the spleen over time.  First, to confirm that ASCs formed after WT 
challenge were not simply delayed in arriving to the BM, we measured IsdB-specific ASCs 8 
weeks after challenge.  BM ASCs induced by Δspa challenge were maintained for 8 weeks; 
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however, the low numbers of ASCs present after WT challenge remained unchanged (Figure 
6A).   The numbers of ASCs present in the spleen declined in both WT and Δspa-challenged 
mice by week 8, to levels that were not different from those in naïve mice (Figure 6B).  This 
indicates that WT challenge did not establish LLPCs in the spleen.   
The main function of LLPCs is the long-term maintenance of antigen-specific Ig as an 
early defense against re-exposure to pathogens [35,44].   We observed similar S. aureus-specific 
IgG responses in the first 2 weeks after challenge with WT or Δspa (Figures 1 and 2).  Since we 
could not detect significant numbers of antigen-specific BM ASCs in WT challenged mice, we 
hypothesized that this serum IgG response would not be maintained over time.  To test this, we 
measured serum IgG in groups of WT or Δspa-challenged mice bi-weekly for 12 weeks after 
challenge.  We found that by 2 weeks post-challenge the levels of IsdB-specific IgG diverged; 
mice challenged with Δspa S. aureus maintained relatively high serum antibody for the 12 week 
period. In contrast, the serum antibody levels in mice challenged with WT S. aureus dropped to 
those detected in uninfected mice (Figure 6C). This is consistent with the lack of BM PC 
accumulation after WT challenge.  Therefore, the presence of SpA during a challenge infection 
did not disrupt the memory B cell and secondary ASC responses, but impaired the accumulation 
of BM ASCs, thereby preventing long-term maintenance of antigen-specific serum IgG.   
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Discussion  
 
S. aureus infections commonly recur without inducing protective immunity [68,225].  
Effective vaccine design is hindered by waning antibody responses and it is unclear whether this 
is due to the inability to form long-lived memory B cells or PCs.  We found that SpA expressed 
on the surface of S. aureus disrupted the long-term maintenance of serum antibody by preventing 
accumulation of LLPCs.  The lack of LLPCs in the BM was not due to defects in memory B cell 
or GC formation and SpA did not impair secondary ASC responses.  Rather, SpA induced an 
expanded short-lived IgM
+
 PB response that did not contribute to the LLPC pool.  
Several studies have described an inverse relationship between ASC expansion and the 
LLPC compartment. First, lowering the B cell activation threshold after secondary Ag exposure 
through the loss of the transcription factor Aiolos augments proliferation of short-lived splenic 
ASCs and relaxes the selection of high affinity PCs.  This leads to a lack of LLPCs in the BM, 
despite normal GCs and chemokine homing [226].  Second, infection with P. chabaudi drives an 
expanded T-independent ASC response while inhibiting long-term maintenance of the T-
dependent antibody response [207].  Third, chronic antigen exposure also favors splenic short-
lived ASC proliferation over LLPCs by altering chemokine production and responsiveness [34].  
In a model of systemic lupus erythematosus where autoantigen is chronically available, ex vivo 
splenic PCs are unresponsive to CXCL12 and diseased mice are unable to generate LLPCs 
[148,220,224].  In our model, ex vivo ASCs from WT challenged mice migrated toward CXCL12 
and similar numbers of ASCs reached the BM within a week after WT or Δspa challenge.  This 
indicates that SpA did not affect chemokine/migration pathways.  Despite normal migration to 
the BM, only Δspa challenge resulted in a continued increase in BM ASC numbers.  This was 
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not due to an inhospitable BM microenvironment because NP-specific ASCs were able to 
accumulate in the BM even when formed during WT S. aureus infection.  
Our study shows an inability to maintain long-term antibody titers and an impaired 
capacity of ASCs to accumulate in the BM after WT challenge.  This may be due to lack of 
survival and/or proliferation.  The present study does not distinguish between these possibilities; 
however, these are ongoing areas of investigation. Although many requirements for LLPC 
survival have been defined, it is not clear what distinguishes short-lived PCs from LLPCs.  There 
is evidence that short- and long-lived ASCs are derived from different precursor populations 
[227] and that their fate is influenced by the environment in which they originate 
[48,61,228,229].  Nonetheless, PBs must proliferate and compete for limited survival factors in 
BM niches in order to become LLPC [227]. Therefore, it is likely that some ASC have the 
potential to thrive in the niches better than others.  How such potential is determined remains 
unclear. Some have suggested that T cell help is required, but LLPCs can be detected after T-
Independent responses [48,49].  We observed increased levels of CD138 on the surface of ASCs 
in the BM after Δspa challenge compared to WT challenge.  Since CD138 is a receptor for 
APRIL, this phenotype may contribute to the ability of the Δspa-derived BMPC population to 
persist.   
Our data rule out a role for defects in BM niches, suggesting that the context of ASC 
differentiation in the spleen was important for determining their fate. We speculate that the 
excess of short-lived PBs driven by SpA in spleen diluted the pool of ASCs that had the potential 
to survive or proliferate in the BM.    Expansion of splenic short-lived extrafollicular ASCs has 
been described following high affinity/avidity BCR stimulation [222,230].  Such interactions are 
also characteristic of SpA binding the F(ab) regions of VhIII BCRs [82].  The excess of short-
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lived ASCs induced by SpA during the secondary response may have occupied vital BM niches 
long enough for the long-lived precursors to miss a window of opportunity to become 
established.  There is evidence that such a window is controlled by transient expansion and 
activation of chemokine-producing BM niche cells [188].  This might explain why the LLPC 
compartment in WT-challenged mice failed to catch up to that observed in Δspa-challenged mice 
several weeks after the splenic ASC response resolved.  
Changes in gene expression allow memory B cells to more rapidly divide compared to 
naïve B cells [22,29].  Memory B cells also express higher levels of co-stimulatory molecules 
and TLRs  [231,232].  SpA-BCR binding increases TLR2 sensitivity, resulting in PB 
proliferation [233]. SpA also mediates BCR uptake of S. aureus, leading to intracellular TLR 
activation [234].   Thus, the effects of SpA may preferentially target the memory population. 
Because the expanded PBs in WT-challenged mice were IgM
+
, memory B cells involved in the 
response would have been IgM memory cells [23,25].  IgM memory B cells may be more 
susceptible to SpA-induced activation because SpA binds IgM with higher affinity than IgG 
[203] and because IgM memory B cells are more likely to be positioned within the marginal zone 
than IgG memory [22,26,235] where exposure to soluble SpA may be enhanced such that short-
lived extrafollicular responses are preferentially driven [236].  In our study, there was 
significantly greater expansion of splenic IgM
+
 PBs after WT challenge compared to primary 
infection, suggesting a significant contribution of IgM memory B cells in addition to naïve cells. 
Nonetheless, the secondary antigen-specific IgG
+ 
ASC response, which derives from both IgG
+ 
and IgM
+ 
memory B cells [27] was similar after WT and Δspa challenge.  This indicates that the 
PB expansion driven by SpA did not diminish the ability of memory cells to respond to S. aureus 
antigens. It is possible that the two responses represent unique responses of the recently 
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described memory B cell subsets [27] to SpA superantigen binding. Development of a flow-
based method to detect S. aureus-specific memory B cells would aid future studies to discern the 
respective roles of different memory B cell subsets in S. aureus infection.   
Our work identifies SpA as a modulator of long-term humoral immunity and 
compliments previous work demonstrating its role in modulating B cells during infection 
[84,194,237].  In these studies, immunization with a purified SpA mutant that does not bind Fc 
or F(ab) regions of Ig (SpAkkaa) or infection with S. aureus expressing the SpAkkaa mutant 
induced anti-SpA neutralizing antibodies that disabled SpA during challenge with S. aureus 
USA300.  As a result, S. aureus-specific antibody production was significantly increased and 
bacterial burden in the kidneys of immunized mice was reduced.  These studies highlight the role 
of SpA in impeding short-term primary and secondary B cell response, but do not address long-
term antibody maintenance.  Our model is different in that SpA is deleted rather than neutralized 
and secondary S. aureus-specific ASC responses were similar in the first 2 weeks after either WT 
or Δspa challenge.  This may be because our choice of strain and inoculum did not induce B cell 
deletion; therefore memory B cells activated in the presence of SpA could still participate in the 
secondary response. Another possibility that is not mutually exclusive is that our model does not 
generate SpA-specific antibodies which may form ICs with SpA that may enhance B cell 
activation.  Nonetheless, after 4 weeks antigen-specific antibody was not replenished in WT-
challenged mice due to the lack of LLPC. Together, these data suggest that eliminating the 
effects of SpA during infection would promote both robust memory and long-term antibody 
maintenance, which are both key for preventing recurring infections [63]. 
In summary, the effects of SpA did not impede the formation of GCs or memory B cells, 
were independent of virulence, and did not disrupt the BM microenvironment. Instead, we found 
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that SpA altered the immune response during challenge infection. The presence of SpA directed 
the secondary ASC response to favor short-lived, extrafollicular PBs that impeded the 
accumulation of LLPCs and attenuated maintenance of long-term antibody. Thus, it is possible 
that previous vaccine attempts have generated B cell memory, but that reinfection in the presence 
of SpA drives an excess of short-lived PBs that contribute to clearance of the infection at hand, 
but not to protection from subsequent infections.  It would be of interest to test the effect of a 
SpA vaccine on the accumulation of LLPC and long-term antibody levels.  Further studies to 
understand the mechanisms by which SpA disrupts BM PC accumulation will inform vaccine 
design for S. aureus and other pathogens. 
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Materials and Methods 
 
Mice  
C57BL/6 mice were bred and maintained in a specific pathogen-free facility at UNC 
Chapel Hill according to the Institutional Animal Care and Use Committee (IACUC) standards.  
All experiments were performed according to the IACUC guidelines.  At 7-8 weeks of age, mice 
were inoculated subcutaneously (s.c.) with 1 x 10
8 
CFU of S. aureus RN4220 (Δspa or WT), 
Newman, or USA300 in 20 μl of 1x PBS.  For challenge experiments, 5 weeks after primary 
inoculation, 1 x 10
6
 CFU were delivered intravenously (IV) via tail vein injection in 100 μl of 1x 
PBS.  For NP-KLH experiments, 100 μg of NP20KLH conjugated to alum (Imject) was delivered 
by intraperitoneal injection.  Immunized mice were boosted (IV) with 100 ug of soluble 
NP20KLH. 
Bacteria 
S. aureus RN4220 (Δspa and WT), Newman and USA300 were grown in brain heart 
infusion (BHI) broth at 37°C overnight and washed and diluted in 1x PBS for infections.  Colony 
forming units (CFUs) were confirmed by plating serial dilutions on BHI plates.  Isogenic S. 
aureus Δspa mutants in Newman and RN4220 were constructed by amplifying ≈ 1b 5’ and 3’ 
homology fragments flanking spa with primers Spa5’.1A 
(CGACTCTAGAGGAAAAACACACTTC) and Spa5’.1B 
(TAAGGATCGGGGACAATACCTACACC) for amplification of the 5’ homology fragment 
and primers Spa3’1A (TACCGAGCTCGAATATCATTTTATCC) and Spa3’1B 
(CAGTGCAGCGGAATTGCTTGGAGTCC) for amplification of the 3’ homology fragment. 
65 
 
The resulting fragments were cloned on either side of a Spec
r
 cassette in the E. coli/S. aureus 
shuttle vector pBT2ts. Allelic exchange was performed as previously described [238] S. aureus 
ΔsrrAB mutants in RN4220 and Newman were generated as previously described [238].  
Kidney burden analysis 
To assess bacterial load in kidneys, 7-8 week-old C57BL/6 mice were infected IV with 1 
x 10
6
 CFU of S. aureus Newman or RN4220 WT, Δspa, or ΔsrrAB.  Kidneys were harvested 5, 7 
or 14 days later.  Kidneys were homogenized in 1x PBS and serial dilutions of homogenate were 
plated on BHI. CFUs were counted after overnight incubation at 37°C.  
ELISA 
For S. aureus ELISAs, vinyl plates were coated with S. aureus RN4220 Δspa grown to 
stationary phase, washed, and diluted 1:10 in 1x PBS.  Plates were coated overnight at 4°C and 
blocked with 0.5% bovine serum albumin (BSA) overnight at 4°C.  Samples were loaded in 
0.5% BSA and incubated overnight at 4°C, incubated with anti-IgG, anti-IgG2, or anti-IgM 
conjugated to alkaline phosphatase for 1 hour at 37°C and developed with p-nitrophenyl 
phosphate.   For IsdB ELISAs, polystyrene plates were coated with 3 μg/ml IsdB (AA40-614) in 
carbonate buffer overnight at 4° and blocked in 0.5% BSA for 1 hour at 37°C.  Plates were 
loaded and developed as for whole S. aureus ELISAs.  
Flow cytometry 
For flow cytometry analysis, spleens and lymph nodes were crushed into single cell 
suspensions in cold 1x PBS.  Bone marrow was harvested from femurs by flushing femur shafts 
with 1x PBS.  Cells were washed and red blood cells (RBCs) lysed with 0.165M NH4Cl.  Cells 
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per sample were labeled with Pacific Orange Live/Dead dye and Fc receptors blocked with 
2.4G2 before antibody staining.  Lymphocytes were identified by forward and side-scatter 
profiles.  GC B cells were identified as CD19
+
 GL7
+
 FAS
+
; Tfh cells as CD4
+
 PD-1
+
 CXCR5
+
; 
ASCs as CD138
+
 B220
lo/neg
; DCs as CD11c
hi
 CD19
-
 CD3
-
 CD49b
-
 Ter119
-
 and CD8α+ or CD8α-; 
pDCs as CD11c
+
 CD19
-
 CD3
-
 CD49b
-
 Ter119
-
 CD45RA
+
; eosinophils as Siglec-F
+
 CD11b
int
.  
For intracellular cytokine analysis, cells were fixed and permeabilized (BD Biosciences) 
overnight at 4°C before staining. For intracellular IL-12, cells were incubated for 3 hours at 37°C 
with 3ug/ml Brefeldin A before fixing.  For chemokine receptor analysis, cells were labeled in 
azide-free buffer at 37°C, then washed in normal buffer on ice to halt recycling.  Data for DC 
analyses were collected on a Becton Dickinson LSR II and analyzed with FlowJo.  All other 
samples were run on a Beckman Coulter CyAn ADP and analyzed with Dako Summit. 
Antibodies and reagents 
Antibodies specific for CD19-PacBlue, CD3e-PE, CD4-PacBlue, PD-1-PE, APRIL-PE, 
CD11c-Alexa488, IL-12p40-Alexa647, Ter119-FITC, CD11c-PE-Cy7, MHCII IA/IE-APC were 
purchased from Biolegend; GL7-FITC, FAS-PE, CXCR5-Biotin, CD138-PE, B220-FITC, IgG-
Biotin, Siglec-F-PacBlue, CD19-FITC, CD8-BrilliantViolet711, CD45RA-Biotin, Streptavidin-
BrilliantViolet421, and Streptavidin-HRP from BD Biosciences; GR-1-Biotin, CXCR4-APC, 
CD3e-FITC, CD49b-FITC, CD40-PE, CD86-PE, CD80-APC from eBiosciences.  IgM (B7.6) 
and anti-Fc (2.4G2) were purified from hybridomas. Live/Dead Pacific Orange and Fixable Blue 
dyes were purchased from Invitrogen/Life Technologies and SDF-1 from Shennendoah 
Biotechnology. Anti-IgG-Alkaline Phosphatase, Anti-IgM- Alkaline Phosphatase, Streptavidin-
Alexa647, and Streptavidin-Alexa488 were purchased from Invitrogen; Anti-IgG2- Alkaline 
Phosphatase from Southern Biotech; p-Nitrophenyl Phosphate tablets, 3-amino-9-ethylcarbazole 
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tablets, PNA-biotin, and Lipopolysaccharide from Sigma; Anti-IgGFc-biotin from Jackson 
immunoresearch; Brefeldin A from LC laboratories. IsdB peptide (AA 40-613) was a generous 
gift from Dr. Benfang Lei (Montana State University). Pokeweed mitogen was a generous gift 
from Dr. Shane Crotty (La Jolla Institute for Allergy & Immunology). 
ELISpot for ex vivo ASC 
Multiscreen ELISpot plates were coated with 1.5 μg/ml IsdB (AA40-613) or NP13BSA in 
1x PBS overnight at 4°C and blocked in 1% BSA overnight at 4°C.  Single cell suspensions of 
RBC-lysed splenocytes or BM cells were resuspended in RPMI supplemented with Sodium 
pyruvate, Gentamicin, Pen/Strep, L-Glutamine, β-ME, and 10% FBS (R10) and plated at 0.5-2 x 
10
6 
cells/well.  Plates were incubated at 37°C for 18 hours, then washed and incubated with anti-
IgG or anti-IgM conjugated to biotin overnight at 4°C.  Plates were washed and incubated in 
streptavidin-HRP for 3 hours RT and developed with 3-amino-9-ethylcarbazole in 
Dimethylformamide. 
ELISpot for memory B cells 
Spleens and lymph nodes were harvested and single cell suspensions were washed and 
RBC-lysed.  Cells were plated in RPMI supplemented with sodium pyruvate, gentamicin, 
pen/strep, L-glutamine, β-ME, and 10% FBS at 0.5 x 106 cells/ml 1:1 with irradiated (1200 rad) 
feeder cells and cultured with 5 μg/ml LPS, 1:10,000, and 1:1000 fixed S. aureus for 5 days at 
37°C.  After 5 days, cells were washed and plated in serial densities (0.25-2 x 10
6 
cells/well) on 
IsdB-coated ELISpot plates prepared and developed as above.  
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Tissue immunofluorescence and microscopy 
Spleens from challenged mice were harvested and fixed in 4% paraformaldehyde for 5hr 
RT. They were washed and hardened in 30% sucrose overnight, then washed and flash frozen in 
OCT (Tissue-Tek).  Sections (6 microns) were fixed in 1:1 MeOH/Acetone and blocked in 0.5% 
Rat serum and 2.4G2 before staining for B220-Alexa647 and IgM-biotin and streptavidin-488 to 
detect extrafollicular foci.  To detect GCs, fixed sections were blocked in 10% FBS and 2.4G2 
and stained with B220-Alexa647 and PNA-biotin and streptavidin-488.  Sections were imaged 
with an Olympus Fluoview 500 (10x objective; numerical aperture of 0.45) and analyzed using 
ImageJ.  
Migration assays 
Splenic B cells were purified by negative selection (Stem Cell Technologies), and 5 x 10
6 
cells were plated in the top chamber in a 5 μm trans well insert (Corning).  For control wells, 
cells were plated in the bottom chamber with no insert.  100 ng/ml of SDF-1 was added to the 
bottom chambers and plates were incubated for 3hr at 37°C. Samples from the bottom and 
control wells were harvested and labelled with CD138 and B220 and enumerated by flow 
cytometry for 120 seconds per sample.  The number of migrated ASCs enumerated from the 
bottom of the trans well was divided by the number enumerated from the corresponding control 
well and expressed as a percent of ASCs in the control well.   
Statistics 
The 1-way ANOVA and Bonferroni-Holm post hoc tests were used to compare multiple 
groups.  The two-sided, unpaired Student’s t test was used for experiments comparing two 
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groups.  In cases where the data was not normally distributed, the Wilcoxon rank sum test was 
used.   
Ethics Statement 
The University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee (IACUC) approved animal care and use protocols performed for this work (12.276 
and 14.018) in accordance with the National Institutes of Health/Public Health Services Animal 
Welfare Assurance Policy (A3410-01) and the United States Department of Agriculture Animal 
Research Facility Regulations (registration number 55-R-044). 
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Table 3. 1 S. aureus strains and mutants 
Strain Mutant Description 
RN4220 Δspa Lacks gene for Protein A 
RN4220 Δsrrab Lacks SrrAB, a regulator of 
virulence factors 
Newman Δspa Lacks gene for Protein A 
Newman Δsrrab Lacks SrrAB, a regulator of 
virulence factors 
USA300 Δspa Lacks gene for Protein A 
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Chapter 3 Figures 
 
Figure 3. 1 Memory B cells are formed and activated in response to S. aureus. 
 (A) Schematic of inoculation and challenge course.  (B-K) Mice were inoculated s.c. with S. 
aureus RN4220 WT or Δspa.  (C-K) Primed or naïve mice were challenged IV with S. aureus 
RN4220 WT or Δspa on day 35 (F-I), 100 (J), or 35 and 90 (K).  (B) S. aureus-specific IgG2 
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measured by ELISA from sera collected on indicated days. n=4-9 mice per group in 3 
experiments.  (C) Representative histograms of GC B cell analysis by flow cytometry on day 14 
post-inoculation.  (C-D) Expression of GC markers GL7 and Fas on B cells from (C) draining 
PLNs or (D) spleens. n=3-6 mice per group per time point in 4 experiments. (E) Memory B cells 
detected by ELISpot 35 days post-inoculation. n=6-8 mice per group in 3 experiments. (F-K) 
(F,G, J, K) S. aureus-specific IgG2 or (H-I) IsdB-specific IgG measured by ELISA from sera 
collected on the indicated days. Sera for G and I were collected on day 14 post-challenge (day 49 
for primed mice). (F) n=9-21 mice per group in 7 experiments; (G) n=5-18 mice per group in 3 
experiments; (H) n=5-16 mice per group in 10 experiments; (I) n=9-12 mice per group in 3 
experiments; (J) n=3-5 mice per group in 2 experiments; (K) n-5-8 mice per group in 4 
experiments. O.D.=optical density. *p<0.05. n.s. not significant.  Error bars=standard error. 
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Figure 3. 2 Protein A induces the expansion of IgM
+ 
plasmablasts  
(A) Schematic of inoculation and challenge course.  Mice were inoculated s.c. with S. aureus 
RN4220 WT or Δspa. On day 35 primed mice and naïve mice were challenged IV with S. aureus 
RN4220 WT or Δspa. Spleens were harvested for analysis 5 days later (day 40). (B) 
Representative histograms of CD138
+
 B220
lo/neg
 ASC analysis in (C).  (C)  Compilation of the 
frequency of CD138
+
 B220
lo/neg
 ASCs from (B). n=2-13 mice per group in 7 experiments.  (D-E) 
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Frequency of surface (D) IgM
+ 
and (E) IgG
+ 
ASCs. n=3-9 mice per group in 4 experiments. (F) 
Anti-IsdB IgG-producing ASCs quantitated by ELISpot. n=4-9 mice per group in 4 experiments.   
FS=forward scatter; SS=side scatter; *p<0.05, **p<0.01, ***p<0.001, n.s. not significant. Error 
bars=standard error. 
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Figure 3. 3 Protein A drives an expanded short-lived extrafollicular response (A-C)  
Mice were inoculated s.c. with S. aureus RN4220 Δspa and challenged IV 35 days later with S. 
aureus RN4220 Δspa or WT. (A) The frequency splenic ASCs at indicated time points. n=3-13 
mice per group per time point over 2-7 experiments.  (B) The frequency of IL-12-producing 
splenic DCs on day 40 (day 5 post-challenge). n=3-12 mice per group in 3 experiments.   
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(C) Day 40 spleen sections labeled with B220 (blue) and IgM (green) to image extrafollicular 
foci. n=5-6 mice per group in 3 experiments. Arrows indicate foci and * indicates bridging 
channels. Full image scale bar=300 microns, inset scale bars=100 microns.  ***p<0.001. Error 
bars=standard error. 
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Figure 3. 4 S. aureus-specific ASCs formed after WT challenge fail to populate the bone 
marrow  
(A-C) Mice were inoculated s.c. with S. aureus RN4220 Δspa and challenged 35 days later with 
S. aureus RN4220 Δspa or WT. (A-B) Anti-IsdB IgG-producing ASCs quantitated from (A) 
bone marrow and (B)  spleens on day 49 (day 14 post-challenge). (A) n=3-14 mice per group in 
7 experiments; (B) n=5-12 mice per group in 10 experiments.  (C) CD19
+
 B cells analyzed for 
expression of GC markers GL7 and Fas on the indicated days. n=3-13 mice per group in 9 
experiments.  *p<0.05, n.s. not significant. Error bars=standard error. 
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Figure 3. 5 Protein A does not disrupt BM niche factors or the migration of ASCs to the BM  
(A-E) Mice were inoculated s.c. with S. aureus RN4220 Δspa and challenged 35 days later with 
S. aureus RN4220 Δspa or WT.  (A) BM CD138+ B220lo/neg ASCs quantitated by flow 
cytometry on the indicated days. n=3-12 mice per group per time point in 2-5 experiments. (B) 
Surface expression of CXCR4 on splenic ASC on day 40 (day 5 post-challenge). n=5-6 mice per 
group in 3 experiments.  (C) Frequency of ASCs that migrated through a trans well membrane 
toward SDF-1(CXCL12). n=2-8 mice per group in 3 experiments. (D-E) The frequency of (D) 
eosinophils and (E) APRIL-producing cells present in BM on day 40 (day 5 post-challenge). 
n=3-6 mice per group in 3 experiments. (F) Mice were immunized with NP20KLH by i.p. 
injection and 35 days later boosted with soluble NP20KLH alone or co-infected IV with S. aureus 
RN4220 Δspa or WT.  On day 49 (day 14 post-boost/infection), NP-specific IgG-producing ASC 
were quantitated by ELISpot. n=2-6 mice per group in 2 experiments.  *p<0.05, n.s.=not 
significant. Error bars=standard error. 
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Figure 3. 6 Protein A prevents long-term maintenance of BM LLPCs and serum antibody   
(A-C) Mice were inoculated s.c. with S. aureus RN4220 Δspa and challenged 35 days later with 
S. aureus RN4220 Δspa or WT. (A-B) Anti-IsdB IgG-producing ASCs quantitated from the (A) 
BM and (B) spleens of challenged mice on days 49 and 91 (day 14 and 56 post-challenge). n=3-6 
mice per group in 3 experiments.  (C) IsdB-specific IgG measured by ELISA from sera collected 
on indicated days. n=4-10 mice per group in 5 experiments. OD=optical density, *p<0.05, 
n.s.=not significant. Error bars=standard error. 
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Supplemental Figure 3. 1  
(A-D) Mice were inoculated s.c. with S. aureus RN4220 WT or Δspa.  (A) Frequency of B cells 
from PLNs. N=2-4 mice per group in 2 experiments. (B) S. aureus-specific IgG measured by 
ELISA from sera collected on indicated days. n=3-4 mice per group in 2 experiments.  (C) 
Frequency of Tfh cells among CD4+ T cells in PLNs. N=2-4 mice per group in 2 experiments.  
(D-F) Primed or naïve mice were infected intravenously (IV) with S. aureus RN4220 WT or 
Δspa and S. aureus-specific IgG was measured by ELISA. (E) was measured on day 14 post-
challenge (day 49 for primed mice). (D) n=7-16 mice per group per time point in 8 experiments; 
(E) n=4-17 mice per group in 5 experiments. (F) S. aureus-specific IgG measured by ELISA in 
sera from mice inoculated s.c. with S. aureus RN4220, Newman, or USA300 and challenged 
with the same strain 35 days later. n=3-8 mice per group in 3 experiments. OD=optical density, 
*p<0.05. 
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Supplemental Figure 3. 2 
(A-B) Mice were inoculated s.c. with S. aureus RN4220 WT or Δspa and challenged 35 days 
later with S. aureus RN4220 Δspa or WT.  (A) The numbers of CD138+ B220lo/neg ASCs and (B) 
the frequency of CD19
+
 B cells in spleens harvested 5 days later (day 40). (A) n=3-13 mice per 
group in 7 experiments; (B) 2-7 mice per group in 3 experiments.  *p<0.05, ***p<0.001, 
n.s.=not significant. Error bars=standard error. 
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Supplemental Figure 3. 3 
(A) Bacterial load in the kidneys of mice infected IV with S. aureus Newman WT or Newman 
Δspa or Newman ΔsrrAB 7 days earlier. n=4-9 mice per group in 2 experiments. (B-D) Mice 
were inoculated s.c. with S. aureus RN4220 Δspa then challenged 35 days later with S. aureus 
RN4220 WT, Δspa, or ΔsrrAB. Spleens were analyzed 5 days later (day 40).  (B) The frequency 
of splenic CD138
+
 B220
lo/neg 
ASCs. n=3-13 mice per group in 7 experiments. (C) Frequency of 
IgM+ PBs. n=3-9 mice per group in 4 cohorts. (D) Frequency of IL12+ DCs. n= 3-12 mice per 
group in 3 experiments. Error bars=standard error. 
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Supplemental Figure 3. 4 
(A-B) Mice were inoculated s.c. with S. aureus RN4220 Δspa and challenged 35 days later with 
S. aureus RN4220 Δspa or WT. Spleens were harvested 5 days later (day 40). (A) The number of 
GC B cells measured. n=2-5 mice per group in 2 experiments. (B) Day 40 spleen sections labeled 
with B220 (Blue), PNA (Magenta), and Thy1.2 (Yellow). n=4-6 mice per group in 2 
experiments. Scale Bar=100 microns. n.s.=not significant. Error bars=standard error. 
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Supplemental Figure 3. 5 
(A) Mice were subcutaneously inoculated with S. aureus RN4220 Δspa then challenged 35 days 
later with S. aureus RN4220 WT, Δspa, or ΔsrrAB. (A) Frequency of BM CD138+ B220lo/neg 
ASCs on day 49 (day 14 post-challenge). n=6-12 mice per group in 7 experiments. (B) Number 
of BM eosinophils. n=3-9 mice per group in 3 experiments. (C) Expression of CD138 on BM 
ASCs on days 45 and 47 (days 10 and 12 post-challenge). n=6-10 mice per group in 3 
experiments. Error bars=standard error. 
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Supplemental Figure 3. 6  Chapter Three Model.  
In the primary adaptive immune response to S. aureus, B cells differentiate into short-lived 
plasma cells, germinal center B cells, and ultimately memory B cells in the absence (A) or 
presence (B) of SpA. (A) Memory B cells respond to Δspa S. aureus (sepsis) during a secondary 
infection by differentiating into short-lived plasmablasts and long-lived plasma cells, mainly in 
the spleen. Long-lived plasma cells then follow the chemotactic signal, CXCL12 (via CXCR4) to 
survival niches in the bone marrow where they constitutively secrete IgG. (B) In response to a 
secondary wild-type infection, however, significantly more short-lived plasmablasts are 
produced, likely as a result of the superantigen activity of SpA. An increase in the frequency IL-
12
+
 DCs due to SpA’s interference of FcγR-IC interactions also potentially contributes to the rise 
in plasmablasts. Plasma cells and plasmablasts formed in the presence of SpA during the 
secondary response are able to respond to chemotactic signals to the bone marrow and some 
arrive within a week of secondary infection. However, the number of plasma cells in the bone 
marrow of wild-type infected mice is not sustained and antigen-specific IgG drops in the serum 
within 4 weeks. This occurs despite the presence of niche factors, APRIL and eosinophils, and 
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the ability of the bone marrow niche to support plasma cells. It is hypothesized that plasma cells 
“imprinted” to become long-lived during the splenic response are crowded out by cells that are 
not. During a window characterized by high expression of CXCL12 from the bone marrow, both 
types of plasma cells migrate to the bone marrow niches, but only the “imprinted” ones survive. 
Because the ratio of “imprinted” to “non-imprinted” is lower after wild-type infection due to 
short-lived plasmablast expansion (B), fewer long-lived cells are sustained compared to the 
number that survive after Δspa infection (A). 
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CHAPTER 4: CONCLUSION 
 
Long-term humoral immunity in protection against disease 
 
Long-term humoral immunity mediated by memory B cells and LLPCs is a key arm of 
protective immunity against many pathogens. Generating either cell type involves a series of 
check points that are still incompletely characterized, particularly in the context of infection. The 
work presented in this thesis identifies previously unappreciated regulatory mechanisms of 
memory B cell formation (Chapter 2) and an immune evasion strategy that disrupts LLPC 
function (Chapter 3) after Staphylococcus aureus infection.  
Chapter 2 describes a role for ICs and BAFF in promoting GCs, Bcl-6, and B cell 
memory. Although it is known that GCs and Bcl-6 expression of GC B cells are pre-requisites 
for class-switched high affinity memory, the molecular mechanisms that decide GC B cell fate 
are not well defined. The work in Chapter 2 identifies BAFF as a key mediator of that decision 
that promotes the transcription factor Bcl-6 and downregulates signals required for PC 
differentiation. Another key feature of this work is the identification of ICs as regulators of the 
earlier primary adaptive immune response. The requirement of IC-FcγR interactions for BAFF in 
the primary response serves as a both a positive feedback mechanism and a regulatory 
checkpoint.   
Chapter 3 represents the first known characterization of memory B cell and PC responses 
to the common pathogen, Staphylococcus aureus and the role of the bacterial protein SpA in 
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modulating long-term humoral immunity. This work provides evidence that B cells are capable 
of forming memory after S. aureus infection, but have not been appreciated as participants in 
protective immunity in part due to the expression of SpA during re-infection. It also identifies 
LLPCs as targets of immune modulation by S. aureus and provides insight that could improve 
vaccine design.   
 
The Role of DCs and ICs in B cell responses 
 
The work presented in Chapters 2 and 3 shed light on two ways that DCs participate in B 
cell fate decisions in response to IC ligation. In Chapter 2, DCs were found to be a sufficient 
source of BAFF required for GC and memory B cell responses. In Chapter 3, DC IL-12 
production is implicated as a driver of PB differentiation. In both cases, DCs integrate input, or 
lack of input, from ICs into signals that are relevant to B cell differentiation.  
Though they are most well-known for presenting antigen to and activating T cells, DCs 
also directly modulate B cells during immune responses. They induce T-independent class 
switch and B cell survival through secretion of BAFF and APRIL and expression of CD40L 
[239]. Other cells make cytokines that impact B cells during an immune response, but DCs are 
uniquely positioned in close proximity to B cells during both T-dependent and T-independent 
responses. DCs carry large intact antigen into spleen [201] and can be found in the FO and MZ, 
in the red pulp of the spleen, and in GCs [112,142,240,241].  B cells also survey incoming DCs 
for Ag that can be carried into the spleen in both MHC-processed and native forms [202,213], 
which places DCs at an ideal position to regulate B cells during their initial exposure to antigen.  
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DCs are also unique in their ability to integrate IC signaling into their responses to 
antigen. DCs co-express activating (FcγRI, III, and IV) and inhibitory (FcγRIIb) receptors for 
IgG, which provides an opportunity to set up thresholds for positive or negative regulation by 
ICs [242]. These signals can enhance antigen presentation [144] and promote secretion of 
cytokines like interferon (IFN) and BAFF [135,136,243], and downregulate other signals, like 
IL-12 [136,148].  
In Chapter 2, we found that DCs lacking FcγRIII (CD16-/-) make less BAFF, resulting in 
reduced B cell Bcl-6 and memory B cell numbers. An understanding of how DC BAFF is 
regulated has important implications for vaccine design. DC BAFF was recently identified as a 
positive regulator of malaria-specific memory B cells, but was defective during malaria infection 
[244]. It would be interesting to determine the role of ICs in BAFF dysregulation during malaria 
infection. Systemic overexpression of BAFF also successfully enhances immunity generated 
against a bacterial vaccine [121]. BAFF’s role in B cell survival, however, makes it a potent 
driver of autoimmunity [245].  The work in Chapter 2 suggests that confining over-expression of 
BAFF to DCs may be a way to achieve specific regulation of antigen-specific B cells while 
limiting the potential for autoimmunity.  
In S. aureus infection, DCs are the main producers of IL-12, which contributes to 
protection [214–216] and enhances T-independent B cell responses [217].  FcγR-/- DCs make 
more IL-12 than wild-type DCs after immunization [148]. IC-FcγR interactions, therefore, are 
needed to downregulate DC IL-12 made in response to innate signals. In Chapter 3, we observed 
an increase in IL-12
+
 DCs and expansion of short-lived extrafollicular PBs after WT but not 
Δspa challenge, suggesting IC-mediated regulation of IL-12 is disrupted by SpA. More work 
should be done to determine if this observation was indeed a direct consequence of SpA 
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interfering with IC-FcγR interactions. This could be accomplished using the recently described 
SpAaa (non-Fab binding) and SpAkk (non-Fc-binding) S. aureus mutants [84]. 
Other cells with Fc receptors may have roles similar to DCs that are worth investigating. 
FcγR ligation on MFs and monocytes, for example, induces pro- and anti-inflammatory cytokine 
secretion [246]. In the NP-KLH model, MFs were not able to restore BAFF-dependent GCs or 
memory (Chapter 2), but they may play similar roles in other contexts. Another example is 
plasmacytoid DCs (pDCs), which make IFN-α as a result of IC-mediated internalization of 
intracellular TLR ligands [243]. Other cells with FcγRs that have been demonstrated to influence 
B cell differentiation include neutrophils, basophils, and mast cells [247]. These were not 
examined in Chapter 2, but it would be worthwhile to determine the respective roles of each 
FcγR+ cell type in IC-mediated regulation of B cell responses.  
 
Translating IC-mediated regulation of memory to S. aureus infection 
 
Model antigens like NP-KLH have provided invaluable details about the requirements for 
GCs, memory B cells, and PCs. However, details learned in a model system are not always 
applicable to every type of immunogen or infection. Model antigens allow us to isolate the roles 
of individual factors in B cell responses that can then be tested in more biologically relevant 
situations. Using NP-KLH, we determined that BAFF made by IC-bound DCs plays a key role in 
successful memory and GC formation through secretion of BAFF (Chapter 2). Disruption of IC-
FcγR interactions with either an Fc-blocking peptide that mimics SpA (Chapter 2) or native SpA 
on S. aureus (Appendix 1) also blocked BAFF secretion in vitro. Despite these findings, in vivo 
infection with S. aureus induced DC BAFF secretion, GC reactions, and B cell memory in the 
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presence or absence of SpA (Chapter 3). This may have occurred because, unlike single-antigen 
T-dependent immunization with NP-KLH, bacterial infection provides many ligands that could 
stimulate BAFF production by DCs or other myeloid cells. TLR stimuli and IFNs can induce 
myeloid DCs to make and/or secrete BAFF [153,248,249].  
Another reason SpA may not block IC-driven BAFF production in vivo is because of its 
low affinity for IgG3 [250]. IgG3 is typically made during T-independent extrafollicular 
responses [8,207,251]. Therefore, the requirement for early IC-driven BAFF may be filled by 
IgG3 during S. aureus infection and perhaps in other contexts where T-independent responses 
are present.  
 
B cells in Staphylococcus aureus infection 
 
Some studies have concluded that B cells are not required for protection against S. aureus 
since B cell knockout mice fare no worse than wild-type mice in regards to bacterial organ 
burden after septic infection [196,252,253]. However, these studies focus on short-term 
responses (7 or 14 days after primary infection or immunization) and lack characterization of the 
B cell response. Further, in one study [253], the loss of B cells resulted in a significant reduction 
in systemic IFN-γ, indicating that B cells promote immunity to S. aureus even if they do not 
directly contribute to bacterial clearance.   
Despite these findings, passive immunization with monoclonal antibodies is protective 
against S. aureus and pre-challenge antibody titers correlate with reduced bacterial organ burden 
in infected mice [179–182].  Clinical studies in humans have also shown correlations between 
pre-existing antigen-specific serum antibody levels and improved clinical outcomes [64,65], and 
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a recent study reported that maintenance of antigen-specific Ab during convalescence correlated 
with reduced recurrence [63]. Mutations that cause defects in antibody production also increase 
the risk of acquiring S. aureus infections [174,254]. Human antibody responses to S. aureus, 
however, are variable and there are no clear predictors indicating which patients will retain high 
titers for long periods of time [69,255]. 
Recent evidence suggests that these observations may be related SpA’s ability to drive 
BCR-mediated activation and sequester IgG from FcγRs. Injection of SpA drives polyclonal B 
cell expansion or deletion of B cells, depending on the inoculum and the presence of co-
stimulation [75,82]. A mutant form of SpA that cannot bind Fab or Fc (SpAkkaa) can be injected 
into mice as a purified protein without causing any B cell deletion, allowing it to be used as a 
vaccine [237]. Vaccination with SpAkkaa or passive immunization with mAbs raised against 
SpAkkaa result in antibody-mediated protection against S. aureus abscess formation [194,237]. 
Inoculation with live S. aureus that express SpAkkaa similarly protects against subsequent 
infection [84]. Serum IgG is also more effective at neutralizing S. aureus expressing the mutant 
SpA compared to wild-type S. aureus [84]. These data point to SpA’s role in negating the effects 
of B cells and antibody on the immune responses to S. aureus and may explain why the absence 
of B cells does not appear to influence short-term clearance of the pathogen. 
Chapter 3 adds to these observations by identifying SpA as a modulator of the long-term 
B cell response. Despite allowing memory B cells to form and function, SpA interfered with 
LLPCs, which are the ultimate products of B cell memory responses. So although affinity 
maturation may be able to proceed and provide protective antibody, the presence of SpA 
prevents that antibody from being maintained.  
93 
 
Negative regulation of long-lived plasma cells by pathogens 
 
LLPCs have been recently recognized as important participants in protection against 
infection and as potential targets of immune modulation by invading pathogens. Disruption of 
long-term humoral immunity may result from defects in the GC response, as is the case for 
Plasmodium chabaudi infection [207]. Another pathogen, Salmonella enterica, disrupts LLPC-
mediated immunity by altering the BM PC niche [34].  
Sepsis and P. chabaudi infection deplete previously generated antigen-specific BM PCs, 
presumably by inducing high levels of IgG that negatively regulate LLPCs through FcγRIIb 
[41,256]; however FcγRIIb-/- mice were defective in initially generating BM PCs, making these 
results difficult to interpret [256]. It is possible that in the context of S. aureus infection, SpA 
prevents negative regulation of splenic PCs via FcγRIIb, which could make competition for 
LLPC establishment in the BM more difficult (discussed in Chapter 3). FcγRIIb-mediated 
regulation of BM PCs, however, is not intrinsic to BM PCs themselves, because FcγRIIb-/-  PCs 
transferred into wild type mice persisted at similar frequencies for the same duration at wild type 
PCs transferred into wild type mice [257]. Therefore, FcγRIIb may not directly regulate BM 
PCs, but may indirectly affect their longevity by regulating their precursors during differentiation 
within secondary lymphoid organs.  
This seems to be the case for PC regulation through the IgM-IC receptor, FcμR. FcμR 
negatively regulates T-independent B cell responses in the spleen [258,259] and loss of FcμR 
reduces PC trafficking to the BM after T-dependent immunization [258]. Interestingly, an IgM-
binding protein expressed by Plasmodium spp. is hypothesized to block the interaction between 
FcμR and IgM [260]. This suggests that it is possible that pathogen disruption of FcμR -mediated 
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regulation is involved in the ultimate disruption of BM PCs by unregulated short-lived splenic 
ASC responses.  
Determining the capacity to become a LLPC 
 
In Chapter 3 we hypothesize that the mechanism that links short-lived ASC expansion to 
the lack of LLPC involves competition between PBs after migration to the BM. This is difficult 
to test because there is no clear way to distinguish PCs that are destined to be long-lived from 
those which are not. Blimp-1 expression is the most well characterized marker of maturity for 
splenic ASCs, though it is not clear whether Blimp-1 can be used to discern PC longevity 
because BM PCs are uniformly Blimp-1
high
 [15]. The surface B cell markers, CD19 and B220 
decrease as Blimp-1 expression increases in splenic ASCs [15]. ASCs found in the BM after WT 
S. aureus challenge expressed higher levels of CD19 and lower levels of CD138 than BM PCs 
from Δspa-challenged mice at time points before the numbers of BM PC were equal (Chapter 3 
and Appendix 2). CD138 is a marker of maturity and a receptor for the PC survival factor, 
APRIL [46,47]. Therefore this phenotype (CD19
+/hi 
CD138
lo
) may be associated with an inability 
to compete for survival in the BM niche. 
This is consistent with a model of “imprinted” longevity for LLPCs which has previously 
been proposed [48]. In the “imprinted” model, some PBs and PCs differentiating in the spleen 
receive signals from T cells or via the BCR that induce expression of genes required for survival 
in the BM [32,48,61]. These genes may include the receptors for survival factors like BAFF or 
APRIL. The BAFF and APRIL receptor, transmembrane activator and CAML interactor (TACI) 
is required for PC differentiation and/or survival [118,261]. TACI
hi
 cells, for example, are least 
likely to express cell-cycle or pro-apoptotic genes [262]. Expression of TACI is regulated by the 
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BCR, TLRs, and CD40L [263]. B cell maturation antigen (BCMA) is another receptor for 
APRIL found highly expressed on PCs. Although the control of BCMA is less well 
characterized, its expression is vital for LLPC survival and maintenance, and activation of the 
pro-survival factor, Mcl-1 [57,264]. 
It is possible that ASCs activated solely by SpA do not receive T cell help and 
consequently lack the signals required to activate receptors like TACI, CD138, or BCMA. This 
is consistent with the observation that SAP
-/- 
mice cannot generate LLPCs [183]and that GC-
derived PCs are formed late in the GC reaction, and thus have experienced multiple rounds of T 
cell help and affinity maturation [10,130]. It is also possible that ASCs derived in the presence of 
SpA lack the appropriate BCR signaling required to upregulate BAFF and APRIL receptors. 
Although a signaling pathway linking SpA to downmodulation of these receptors is not clear, it 
may involve Bruton’s tyrosine kinase (Btk), which is downstream of the BCR and TLRs and is 
required for TACI expression [263,265]. Interestingly, the loss of Btk is associated with an 
increase in extrafollicular responses [2]. The fact that most of the expanded PB population 
induced by SpA was surface IgM
+
 may also be important if the differences in IgG and IgM 
BCR-proximal signaling [266,267] are related to expression of genes required for BM LLPC 
survival. The frequency of IgM
+ 
ASCs in the BM as well as the expression of TACI and BCMA 
on ASCs from WT versus Δspa-challenged mice is currently under study. 
The mechanism that prevents ASCs formed after WT S. aureus challenge from 
populating the BM between days 5 and 14 post-challenge remains to be defined. If the 
“imprinting” model is correct, both imprinted and non-imprinted ASCs would be competent to 
migrate to the BM during a window of high expression of chemotactic and survival signals in the 
BM [188]. After that window is closed, however, the imprinted cells would outcompete those 
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without high expression of survival signals. In the case of WT-challenge mice, the expansion of 
“non-imprinted” cells may limit the number of “imprinted” cells that arrive in the BM. For 
reasons that are not yet clear, the imprinted cells do not rebound in the WT-challenged mice 
since by eight weeks post-challenge, WT-challenged mice have a similar number of IsdB-
specific BM PCs as naïve mice (Chapter 3). To understand whether “imprinting” provides a 
survival advantage, a proliferative advantage, or both, future work should be done to analyze the 
frequency of apoptotic (Annexin V
+
) and dividing (Ki67
+ 
or BrdU
+
) ASCs in the BM of WT and 
Δspa-challenged mice over time. 
 
Relevance for human vaccine design 
 
Both Chapters 2 and 3 have important implications for vaccine design. The results of 
Chapter 2 suggest that BAFF could be used to augment vaccine responses and that local, DC-
derived BAFF is sufficient to improve T-dependent GC responses and B cell memory. Long-
term, genetic manipulation or IC stimulation of DCs could be used to enhance vaccines for 
which better adjuvants are needed, or for DC-based cancer vaccine therapies.  
Chapter 3 reveals an important mechanism of immune modulation that could be exploited 
to improve the efficacy of vaccines against S. aureus. Vaccines comprised of whole bacteria 
deficient for SpA do generate humoral memory, but are not protective against WT (SpA
+
) 
infection ([268] and Appendix 3). Induction of SpA-neutralizing antibody is a better strategy that 
has been proven effective at reducing abscess formation and increasing short-term antibody 
responses in mice [84,194]. The data in Chapter 3 indicate that long-term antibody titers will be 
an important measure of the effectiveness of any vaccine strategy that neutralizes SpA. Two 
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important variables to consider in pursuing this strategy are the expression levels of SpA by an 
infecting strain and the frequency of VhIII host B cells. It would be useful to discern whether 
these factors are related to the observed variability in long-term antibody levels among 
individuals recovering from S. aureus infections. 
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APPENDIX 1 
 
Figure 4. 1 Staphylococcus Protein A interferes with IC-induced DC BAFF in vitro but not in 
vivo  
Previous work by our lab has shown that immune complex (IC) ligation of Fc receptors (FcγR) 
induces BAFF production by DCs which in turn directs B and T lymphocyte populations to 
generate memory.  We hypothesized that SpA on S. aureus would sequester ICs and prevent 
FcγR ligation on DCs and BAFF production. To test this, DCs derived from the bone marrow 
were cultured with ICs and secreted BAFF was measured by ELISpot (see Chapter 2 Methods) 
in the presence or absence of S. aureus RN4220 WT or Δspa (1 x 106 CFU) (A). n=5. To 
determine whether SpA could inhibit IC-FyR interactions in vivo, we infected mice IV with 1 x 
10
6
 CFU S. aureus RN4220 WT or Δspa. After 7 days, CD11c+ DCs were isolated from the 
spleen by positive selection and plated onto a BAFF ELISpot (B). n=2 mice per group. *p<0.05, 
**p<0.01, ***p<0.001, n.s.=not significant. 
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APPENDIX 2 
 
Figure 4. 2 BM ASCs formed in the presence of SpA express more CD19 than on those formed 
after Δspa challenge. 
CD19 expression is reduced as ASCs mature into PCs. To compare the maturity of ASCs found 
in the BM of mice challenged with S. aureus RN4220 WT or Δspa, CD138+ B220lo/neg BM ASCs 
were analyzed by flow cytometry 10 and 12 days after challenge to measure the levels of CD19 
(see Chapter 3 Methods). n=6-10 mice per group in 4 experiments. *p<0.05 
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APPENDIX 3 
 
Figure 4. 3 Inoculation with Δspa S. aureus does not protect mice from septic infection after WT 
challenge 
(A) To determine whether SpA interferes with the production of a protective immune memory 
response, we infected mice S.C. with S. aureus Newman Δspa (1 x 108 CFU). After 35 days, 
naïve or pre-infected mice were challenged I.V. with S. aureus Newman Δspa or WT (1 x 106). 
After 7 days, the numbers of CFUs in the kidneys were measured (see Chapter 3 Methods). n=4-
9 mice per group in 2 experiments. (B) To test whether the long-term maintenance of BM PCs 
and circulating IgG was protective against septic infection, we infected mice S.C. and challenged 
them 35 days later as in (A). After 14 weeks (Day 133), mice were challenged I.V. a second time 
with S. aureus Newman WT and 7 days later, kidneys were harvested and analyzed for bacterial 
CFUs as in (A). n=6-8 mice per group in 3 experiments. Data are not statistically significant.  
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